Tables | Volume 34 | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	30,444	—	29,602	—	28,809	—	24,174	—	28,304	—
Female	7,288	—	7,055	—	6,900	—	5,421	—	6,554	—
Transgender woman/girl^b	651	—	661	—	692	—	676	—	811	—
Transgender man/boy^b	32	—	48	—	45	—	41	—	56	—
Additional gender identity^c	18	—	19	—	32	—	23	—	44	—
Age at diagnosis (yr)
< 13	105	0.2	86	0.2	57	0.1	60	0.1	53	0.1
13–14	25	0.3	20	0.2	21	0.3	12	0.1	15	0.2
15–19	1,791	8.5	1,722	8.2	1,652	7.8	1,264	5.9	1,452	6.7
20–24	6,481	29.4	6,123	28.1	5,987	27.7	4,849	22.6	5,460	25.4
25–29	7,720	33.0	7,682	32.6	7,382	31.4	6,080	26.7	6,713	30.0
30–34	5,680	25.9	5,664	25.6	5,645	25.1	5,199	22.7	6,368	27.6
35–39	4,254	20.1	4,186	19.4	4,102	18.9	3,400	15.3	4,403	19.7
40–44	2,981	15.2	2,964	15.1	2,946	14.8	2,474	12.0	3,140	14.9
45–49	2,926	14.0	2,759	13.3	2,571	12.6	2,044	10.1	2,326	11.8
50–54	2,637	12.4	2,435	11.7	2,303	11.3	1,828	8.8	2,116	10.1
55–59	1,869	8.5	1,824	8.3	1,837	8.4	1,558	7.1	1,786	8.3
60–64	1,082	5.4	1,042	5.1	1,106	5.4	879	4.2	1,095	5.2
≥ 65	882	1.7	878	1.7	869	1.6	688	1.3	842	1.5
Race/ethnicity
American Indian/Alaska Native	193	8.0	170	7.1	194	8.0	190	7.8	223	9.1
Asian	919	5.0	850	4.5	728	3.8	612	3.1	739	3.8
Black/African American	16,163	39.8	15,642	38.2	15,327	37.2	12,678	30.4	14,555	34.8
Hispanic/Latino^d	10,010	17.1	9,931	16.7	9,858	16.3	8,046	13.0	10,070	16.1
Native Hawaiian/other Pacific Islander	47	8.1	57	9.6	59	9.8	64	10.3	76	12.1
White	9,558	4.8	9,338	4.7	8,992	4.6	7,744	3.9	9,063	4.6
Multiracial	1,543	22.0	1,397	19.4	1,320	17.9	1,001	13.1	1,043	13.4
Transmission category^e
Male sex at birth (≥ 13 yrs at diagnosis)^f
Male-to-male sexual contact^g	25,345	—	24,464	—	23,870	—	20,460	—	23,855	—
Injection drug use^h	1,291	—	1,376	—	1,362	—	1,170	—	1,415	—
Male-to-male sexual contact^g and injection drug use^h	1,517	—	1,531	—	1,581	—	1,185	—	1,373	—
Heterosexual contactⁱ	2,882	—	2,839	—	2,643	—	2,006	—	2,460	—
Perinatal^j	14	—	16	—	22	—	9	—	11	—
Other^k	18	—	17	—	20	—	16	—	18	—
Subtotal	31,067	23.3	30,242	22.6	29,498	21.9	24,846	18.1	29,132	21.1
Female sex at birth (≥ 13 yrs at diagnosis)^f
Injection drug use^h	1,109	—	1,117	—	1,182	—	895	—	1,075	—
Heterosexual contactⁱ	6,106	—	5,892	—	5,695	—	4,494	—	5,456	—
Perinatal^j	40	—	40	—	38	—	34	—	49	—
Other^k	6	—	7	—	7	—	6	—	5	—
Subtotal	7,261	5.2	7,057	5.0	6,923	4.9	5,429	3.8	6,584	4.6
Child (< 13 yrs at diagnosis)
Perinatal	89	—	69	—	47	—	51	—	39	—
Other^k	16	—	17	—	10	—	9	—	14	—
Subtotal	105	0.2	86	0.2	57	0.1	60	0.1	53	0.1
Region of residence^l
Northeast	5,998	10.7	5,560	9.9	5,323	9.5	4,252	7.4	4,993	8.7
Midwest	5,119	7.5	4,953	7.3	4,774	7.0	4,115	6.0	4,824	7.0
South	19,707	15.9	19,273	15.5	18,982	15.1	15,566	12.3	18,728	14.7
West	7,609	9.8	7,599	9.8	7,399	9.4	6,402	8.1	7,224	9.2
Total	38,433	11.8	37,385	11.4	36,478	11.1	30,335	9.2	35,769	10.8

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Data include transgender and additional gender identity persons.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^l Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	30,811	—	29,980	—	29,148	—	24,435	—	28,641	—
Female	7,382	—	7,136	—	6,983	—	5,467	—	6,636	—
Transgender woman/girl^b	653	—	665	—	694	—	679	—	812	—
Transgender man/boy^b	32	—	48	—	45	—	41	—	56	—
Additional gender identity^c	18	—	19	—	32	—	23	—	44	—
Age at diagnosis (yr)
< 13	105	0.2	86	0.2	57	0.1	60	0.1	53	0.1
13–14	25	0.3	20	0.2	21	0.2	12	0.1	15	0.2
15–19	1,804	8.4	1,740	8.2	1,658	7.8	1,272	5.8	1,460	6.7
20–24	6,547	29.3	6,188	28.0	6,045	27.6	4,893	22.5	5,512	25.3
25–29	7,782	33.0	7,759	32.6	7,442	31.3	6,124	26.6	6,793	30.0
30–34	5,741	25.9	5,723	25.6	5,703	25.2	5,237	22.7	6,411	27.5
35–39	4,306	20.1	4,222	19.4	4,142	18.9	3,438	15.3	4,448	19.8
40–44	3,017	15.2	3,005	15.1	2,984	14.8	2,502	12.0	3,186	14.9
45–49	2,968	14.0	2,805	13.4	2,609	12.7	2,067	10.1	2,359	11.8
50–54	2,687	12.5	2,484	11.8	2,334	11.3	1,859	8.8	2,160	10.2
55–59	1,906	8.6	1,853	8.4	1,875	8.5	1,585	7.1	1,807	8.3
60–64	1,105	5.5	1,062	5.2	1,133	5.4	896	4.2	1,116	5.2
≥ 65	903	1.8	901	1.7	899	1.6	700	1.3	869	1.5
Race/ethnicity
American Indian/Alaska Native	193	—	170	—	194	—	190	—	223	—
Asian	922	—	854	—	735	—	612	—	740	—
Black/African American	16,168	—	15,654	—	15,335	—	12,685	—	14,561	—
Hispanic/Latino^d	10,456	—	10,369	—	10,257	—	8,347	—	10,478	—
Native Hawaiian/other Pacific Islander	50	—	59	—	63	—	65	—	76	—
White	9,562	—	9,344	—	8,998	—	7,745	—	9,068	—
Multiracial	1,545	—	1,398	—	1,320	—	1,001	—	1,043	—
Transmission category^e
Male sex at birth (≥ 13 yrs at diagnosis)^f
Male-to-male sexual contact^g	25,587	—	24,742	—	24,110	—	20,660	—	24,107	—
Injection drug use^h	1,325	—	1,401	—	1,385	—	1,189	—	1,436	—
Male-to-male sexual contact^g and injection drug use^h	1,529	—	1,542	—	1,594	—	1,190	—	1,375	—
Heterosexual contactⁱ	2,962	—	2,906	—	2,709	—	2,046	—	2,523	—
Perinatal^j	14	—	16	—	22	—	9	—	11	—
Other^k	18	—	17	—	20	—	16	—	18	—
Subtotal	31,436	23.3	30,624	22.6	29,839	21.9	25,110	18.1	29,470	21.1
Female sex at birth (≥ 13 yrs at diagnosis)^f
Injection drug use^h	1,118	—	1,120	—	1,188	—	898	—	1,077	—
Heterosexual contactⁱ	6,190	—	5,970	—	5,773	—	4,536	—	5,536	—
Perinatal^j	40	—	40	—	38	—	34	—	49	—
Other^k	6	—	7	—	7	—	6	—	5	—
Subtotal	7,355	5.2	7,138	5.0	7,006	4.9	5,475	3.8	6,666	4.6
Child (< 13 yrs at diagnosis)
Perinatal	89	—	69	—	47	—	51	—	39	—
Other^k	16	—	17	—	10	—	9	—	14	—
Subtotal	105	0.2	86	0.2	57	0.1	60	0.1	53	0.1
Region of residence^l
Northeast	5,998	10.7	5,560	9.9	5,323	9.5	4,252	7.4	4,993	8.7
Midwest	5,119	7.5	4,953	7.3	4,774	7.0	4,115	6.0	4,824	7.0
South	19,707	15.9	19,273	15.5	18,982	15.1	15,566	12.3	18,728	14.7
West	7,609	9.8	7,599	9.8	7,399	9.4	6,402	8.1	7,224	9.2
U.S. dependent areas	463	12.4	463	12.9	424	11.8	310	8.4	420	11.5
Total	38,896	11.8	37,848	11.5	36,902	11.1	30,645	9.1	36,189	10.8

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Data include transgender and additional gender identity persons.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^l Data are based on residence at time of diagnosis of HIV infection.

Table 2a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2021—United States
	American Indian/Alaska Native		Asian		Black/African American		Hispanic/Latino^a		Native Hawaiian/other Pacific Islander		White		Multiracial		Total
	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b
Gender
Male	167	—	627	—	10,611	—	8,626	—	60	—	7,412	—	801	—	28,304	—
Female	46	—	93	—	3,540	—	1,159	—	10	—	1,505	—	201	—	6,554	—
Transgender woman/girl^c	10	—	17	—	374	—	257	—	6	—	112	—	35	—	811	—
Transgender man/boy^c	0	—	2	—	18	—	14	—	0	—	19	—	3	—	56	—
Additional gender identity^d	0	—	0	—	12	—	14	—	0	—	15	—	3	—	44	—
Age at diagnosis (yr)
< 13	0	0.0	2	0.1	33	0.5	11	0.1	0	0.0	5	0.0	2	0.1	53	0.1
13–14	0	0.0	0	0.0	8	0.7	6	0.3	0	0.0	1	0.0	0	0.0	15	0.2
15–19	12	6.7	23	2.0	825	28.2	368	6.9	6	13.9	156	1.4	62	7.6	1,452	6.7
20–24	21	11.6	94	7.7	2,864	94.8	1,480	29.8	5	11.7	814	7.1	182	25.6	5,460	25.4
25–29	49	25.9	142	9.7	2,776	84.8	2,082	42.8	15	31.7	1,447	12.1	202	32.6	6,713	30.0
30–34	42	22.4	132	7.8	2,443	74.5	1,931	40.9	13	24.2	1,617	12.8	190	38.3	6,368	27.6
35–39	33	20.1	96	5.7	1,515	52.9	1,368	29.7	12	23.1	1,263	10.1	116	29.0	4,403	19.7
40–44	16	10.6	75	4.9	1,052	38.8	929	21.2	9	19.9	976	8.2	83	24.2	3,140	14.9
45–49	15	10.8	48	3.3	823	33.0	658	16.6	3	7.8	721	6.3	58	20.6	2,326	11.8
50–54	19	13.2	59	4.5	701	27.2	523	14.7	7	19.0	746	5.7	61	23.7	2,116	10.1
55–59	6	3.9	31	2.7	707	27.0	354	11.5	2	5.6	640	4.5	46	19.5	1,786	8.3
60–64	6	4.1	19	1.8	456	18.6	206	8.4	2	6.3	389	2.6	17	7.8	1,095	5.2
≥ 65	4	1.2	18	0.7	352	6.7	154	3.0	2	3.0	288	0.7	24	5.0	842	1.5
Transmission category^e
Male sex at birth (≥ 13 yrs at diagnosis)^f
Male-to-male sexual contact^g	141	—	573	—	8,879	—	7,757	—	59	—	5,758	—	688	—	23,855	—
Injection drug use^h	10	—	14	—	371	—	299	—	1	—	679	—	41	—	1,415	—
Male-to-male sexual contact^g and injection drug use^h	16	—	17	—	244	—	325	—	4	—	714	—	54	—	1,373	—
Heterosexual contactⁱ	11	—	40	—	1,470	—	506	—	3	—	379	—	52	—	2,460	—
Perinatal^j	0	—	0	—	8	—	3	—	0	—	0	—	0	—	11	—
Other^k	0	—	1	—	6	—	4	—	0	—	6	—	1	—	18	—
Subtotal	177	17.7	644	8.1	10,978	66.5	8,895	35.7	66	25.5	7,536	8.9	836	32.7	29,132	21.1
Female sex at birth (≥ 13 yrs at diagnosis)^f
Injection drug use^h	17	—	6	—	300	—	161	—	3	—	553	—	35	—	1,075	—
Heterosexual contactⁱ	29	—	85	—	3,207	—	997	—	7	—	962	—	169	—	5,456	—
Perinatal^j	0	—	2	—	35	—	6	—	0	—	5	—	1	—	49	—
Other^k	0	—	1	—	2	—	0	—	0	—	2	—	0	—	5	—
Subtotal	46	4.4	93	1.1	3,544	19.5	1,164	4.8	10	3.9	1,522	1.8	205	7.6	6,584	4.6
Child (< 13 yrs at diagnosis)
Perinatal	0	—	1	—	26	—	8	—	0	—	3	—	1	—	39	—
Other^k	0	—	1	—	7	—	3	—	0	—	2	—	1	—	14	—
Subtotal	0	0.0	2	0.1	33	0.5	11	0.1	0	0.0	5	0.0	2	0.1	53	0.1
Region of residence^l
Northeast	5	3.8	141	3.5	1,952	30.0	1,625	18.5	4	17.2	1,094	3.0	172	16.2	4,993	8.7
Midwest	47	11.2	80	3.3	2,102	28.8	725	12.4	6	14.6	1,700	3.3	164	11.0	4,824	7.0
South	56	6.8	210	4.4	9,259	37.9	4,422	18.5	19	18.3	4,220	6.0	542	20.7	18,728	14.7
West	115	10.7	308	3.7	1,242	34.1	3,298	13.7	47	10.3	2,049	5.3	165	6.3	7,224	9.2
Total	223	9.1	739	3.8	14,555	34.8	10,070	16.1	76	12.1	9,063	4.6	1,043	13.4	35,769	10.8

Note: Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.
^b Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Data presented include transgender and additional gender identity persons.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^l Data are based on residence at time of diagnosis of HIV infection.

Table 2b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2021—United States and 6 dependent areas
	American Indian/Alaska Native	Asian	Black/African American	Hispanic/Latino^a	Native Hawaiian/other Pacific Islander	White	Multiracial	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Gender
Male	167	628	10,616	8,952	60	7,417	801	28,641
Female	46	93	3,541	1,240	10	1,505	201	6,636
Transgender woman/girl^b	10	17	374	258	6	112	35	812
Transgender man/boy^b	0	2	18	14	0	19	3	56
Additional gender identity^c	0	0	12	14	0	15	3	44
Age at diagnosis (yr)
< 13	0	2	33	11	0	5	2	53
13–14	0	0	8	6	0	1	0	15
15–19	12	23	825	376	6	156	62	1,460
20–24	21	94	2,865	1,531	5	814	182	5,512
25–29	49	143	2,776	2,160	15	1,448	202	6,793
30–34	42	132	2,444	1,973	13	1,617	190	6,411
35–39	33	96	1,515	1,412	12	1,264	116	4,448
40–44	16	75	1,052	975	9	976	83	3,186
45–49	15	48	823	690	3	722	58	2,359
50–54	19	59	703	565	7	746	61	2,160
55–59	6	31	708	373	2	641	46	1,807
60–64	6	19	457	225	2	390	17	1,116
≥ 65	4	18	352	181	2	288	24	869
Transmission category^d
Male sex at birth (≥ 13 yrs at diagnosis)^e
Male-to-male sexual contact^f	141	574	8,883	8,000	59	5,762	688	24,107
Injection drug use^g	10	14	373	318	1	679	41	1,436
Male-to-male sexual contact^f and injection drug use^g	16	17	244	327	4	714	54	1,375
Heterosexual contact^h	11	40	1,470	569	3	379	52	2,523
Perinatalⁱ	0	0	8	3	0	0	0	11
Other^j	0	1	6	4	0	6	1	18
Subtotal	177	645	10,983	9,222	66	7,541	836	29,470
Female sex at birth (≥ 13 yrs at diagnosis)^e
Injection drug use^g	17	6	301	162	3	553	35	1,077
Heterosexual contact^h	29	85	3,208	1,077	7	962	169	5,536
Perinatalⁱ	0	2	35	6	0	5	1	49
Other^j	0	1	2	0	0	2	0	5
Subtotal	46	93	3,545	1,245	10	1,522	205	6,666
Child (< 13 yrs at diagnosis)
Perinatal	0	1	26	8	0	3	1	39
Other^j	0	1	7	3	0	2	1	14
Subtotal	0	2	33	11	0	5	2	53
Region of residence^k
Northeast	5	141	1,952	1,625	4	1,094	172	4,993
Midwest	47	80	2,102	725	6	1,700	164	4,824
South	56	210	9,259	4,422	19	4,220	542	18,728
West	115	308	1,242	3,298	47	2,049	165	7,224
U.S. dependent areas	0	1	6	408	0	5	0	420
Total	223	740	14,561	10,478	76	9,068	1,043	36,189

Note: Numbers less than 12 should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Data include transgender and additional gender identity persons.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Data are based on residence at time of diagnosis of HIV infection.

Table 3a. Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, assigned sex at birth, and selected characteristics, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at diagnosis (yr)
13–14	13	0.3	11	0.3	12	0.3	6	0.1	8	0.2
15–19	1,541	14.3	1,480	13.8	1,449	13.5	1,107	10.1	1,250	11.3
20–24	5,711	50.5	5,399	48.3	5,262	47.5	4,288	39.2	4,840	44.1
25–29	6,741	56.7	6,738	56.1	6,443	53.6	5,310	45.9	5,867	51.6
30–34	4,667	42.1	4,713	42.1	4,690	41.2	4,391	37.9	5,411	46.3
35–39	3,338	31.5	3,265	30.3	3,202	29.4	2,693	24.0	3,475	30.9
40–44	2,241	23.1	2,175	22.2	2,189	22.1	1,911	18.4	2,368	22.4
45–49	2,165	20.9	2,040	19.9	1,885	18.7	1,493	14.7	1,676	17.0
50–54	1,976	18.8	1,780	17.3	1,680	16.7	1,379	13.3	1,543	14.8
55–59	1,311	12.3	1,286	12.1	1,322	12.4	1,139	10.5	1,283	12.1
60–64	751	7.9	722	7.4	758	7.7	614	6.0	809	7.8
≥ 65	612	2.7	633	2.7	606	2.5	515	2.1	602	2.4
Race/ethnicity
American Indian/Alaska Native	150	15.7	140	14.5	150	15.4	149	15.0	177	17.7
Asian	797	10.9	742	9.9	624	8.2	527	6.7	644	8.1
Black/African American	11,861	75.4	11,621	73.1	11,476	71.5	9,744	59.5	10,978	66.5
Hispanic/Latino^c	8,814	38.9	8,729	37.7	8,673	36.7	7,115	29.1	8,895	35.7
Native Hawaiian/other Pacific Islander	39	16.5	53	21.9	52	21.1	49	19.3	66	25.5
White	8,128	9.7	7,865	9.4	7,473	8.9	6,445	7.6	7,536	8.9
Multiracial	1,278	58.0	1,092	47.9	1,050	44.5	817	33.1	836	32.7
Region of residence^d
Northeast	4,662	20.2	4,332	18.7	4,161	18.0	3,362	14.0	3,942	16.5
Midwest	4,155	14.9	4,016	14.3	3,798	13.5	3,366	11.8	3,922	13.7
South	15,580	31.1	15,302	30.2	15,133	29.6	12,552	24.2	14,996	28.7
West	6,670	20.9	6,592	20.4	6,406	19.7	5,566	16.9	6,272	18.9
Subtotal	31,067	23.3	30,242	22.6	29,498	21.9	24,846	18.1	29,132	21.1
Female sex at birth^b
Age at diagnosis (yr)
13–14	12	0.3	9	0.2	9	0.2	6	0.1	7	0.2
15–19	250	2.4	242	2.3	203	2.0	157	1.5	202	1.9
20–24	770	7.2	724	6.8	725	6.9	561	5.3	620	5.9
25–29	979	8.5	944	8.2	939	8.2	770	6.9	846	7.7
30–34	1,013	9.3	951	8.7	955	8.6	808	7.1	957	8.4
35–39	916	8.6	921	8.6	900	8.3	707	6.4	928	8.4
40–44	740	7.5	789	8.0	757	7.6	563	5.5	772	7.3
45–49	761	7.2	719	6.9	686	6.7	551	5.4	650	6.6
50–54	661	6.1	655	6.2	623	6.0	449	4.3	573	5.5
55–59	558	4.9	538	4.8	515	4.6	419	3.7	503	4.6
60–64	331	3.2	320	3.0	348	3.2	265	2.5	286	2.6
≥ 65	270	1.0	245	0.8	263	0.9	173	0.6	240	0.8
Race/ethnicity
American Indian/Alaska Native	43	4.3	30	3.0	43	4.2	40	3.9	46	4.4
Asian	114	1.4	102	1.2	98	1.1	83	1.0	93	1.1
Black/African American	4,246	24.1	3,972	22.3	3,820	21.3	2,899	16.0	3,544	19.5
Hispanic/Latino^c	1,181	5.3	1,192	5.2	1,178	5.0	922	3.9	1,164	4.8
Native Hawaiian/other Pacific Islander	7	3.0	4	1.7	7	2.9	14	5.6	10	3.9
White	1,415	1.6	1,458	1.7	1,512	1.7	1,287	1.5	1,522	1.8
Multiracial	255	10.9	299	12.3	265	10.6	184	7.1	205	7.6
Region of residence^d
Northeast	1,326	5.4	1,220	4.9	1,156	4.7	879	3.5	1,046	4.2
Midwest	944	3.2	925	3.2	969	3.3	740	2.5	893	3.0
South	4,065	7.7	3,923	7.3	3,817	7.1	2,985	5.5	3,707	6.8
West	926	2.9	989	3.0	981	3.0	825	2.5	938	2.8
Subtotal	7,261	5.2	7,057	5.0	6,923	4.9	5,429	3.8	6,584	4.6
Total	38,328	14.1	37,299	13.6	36,421	13.2	30,275	10.9	35,716	12.7

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.
^b Data include transgender and additional gender identity persons.
^c Hispanic/Latino persons can be of any race.
^d Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, assigned sex at birth, and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at diagnosis (yr)
13–14	13	0.3	11	0.3	12	0.3	6	0.1	8	0.2
15–19	1,551	14.2	1,496	13.7	1,455	13.4	1,115	10.0	1,256	11.3
20–24	5,772	50.4	5,455	48.3	5,315	47.5	4,327	39.1	4,883	44.0
25–29	6,792	56.5	6,808	56.1	6,498	53.5	5,350	45.7	5,944	51.7
30–34	4,721	42.2	4,766	42.2	4,739	41.3	4,428	37.9	5,449	46.2
35–39	3,378	31.6	3,297	30.3	3,236	29.4	2,728	24.1	3,507	30.9
40–44	2,270	23.1	2,208	22.3	2,215	22.1	1,932	18.4	2,401	22.4
45–49	2,192	20.9	2,072	20.0	1,912	18.8	1,511	14.7	1,702	17.0
50–54	2,014	19.0	1,818	17.5	1,704	16.7	1,405	13.4	1,576	14.9
55–59	1,335	12.4	1,307	12.1	1,347	12.5	1,158	10.6	1,301	12.1
60–64	769	8.0	737	7.5	779	7.8	628	6.1	823	7.9
≥ 65	629	2.8	649	2.8	627	2.6	522	2.1	620	2.4
Race/ethnicity
American Indian/Alaska Native	150	—	140	—	150	—	149	—	177	—
Asian	800	—	746	—	631	—	527	—	645	—
Black/African American	11,863	—	11,632	—	11,481	—	9,749	—	10,983	—
Hispanic/Latino^c	9,171	—	9,087	—	8,993	—	7,372	—	9,222	—
Native Hawaiian/other Pacific Islander	42	—	55	—	55	—	50	—	66	—
White	8,131	—	7,871	—	7,479	—	6,446	—	7,541	—
Multiracial	1,279	—	1,093	—	1,050	—	817	—	836	—
Region of residence^d
Northeast	4,662	20.2	4,332	18.7	4,161	18.0	3,362	14.0	3,942	16.5
Midwest	4,155	14.9	4,016	14.3	3,798	13.5	3,366	11.8	3,922	13.7
South	15,580	31.1	15,302	30.2	15,133	29.6	12,552	24.2	14,996	28.7
West	6,670	20.9	6,592	20.4	6,406	19.7	5,566	16.9	6,272	18.9
U.S. dependent areas	369	24.4	382	26.0	341	23.1	264	17.4	338	22.2
Subtotal	31,436	23.3	30,624	22.6	29,839	21.9	25,110	18.1	29,470	21.1
Female sex at birth^b
Age at diagnosis (yr)
13–14	12	0.3	9	0.2	9	0.2	6	0.1	7	0.2
15–19	253	2.4	244	2.3	203	1.9	157	1.5	204	1.9
20–24	775	7.1	733	6.8	730	6.8	566	5.3	629	5.9
25–29	990	8.5	951	8.2	944	8.1	774	6.8	849	7.6
30–34	1,020	9.3	957	8.7	964	8.6	809	7.1	962	8.3
35–39	928	8.7	925	8.5	906	8.3	710	6.4	941	8.4
40–44	747	7.5	797	8.0	769	7.6	570	5.5	785	7.4
45–49	776	7.3	733	6.9	697	6.7	556	5.4	657	6.6
50–54	673	6.1	666	6.2	630	6.0	454	4.3	584	5.5
55–59	571	5.0	546	4.8	528	4.6	427	3.8	506	4.6
60–64	336	3.2	325	3.0	354	3.3	268	2.5	293	2.7
≥ 65	274	1.0	252	0.9	272	0.9	178	0.6	249	0.8
Race/ethnicity
American Indian/Alaska Native	43	—	30	—	43	—	40	—	46	—
Asian	114	—	102	—	98	—	83	—	93	—
Black/African American	4,249	—	3,973	—	3,823	—	2,901	—	3,545	—
Hispanic/Latino^c	1,270	—	1,272	—	1,257	—	966	—	1,245	—
Native Hawaiian/other Pacific Islander	7	—	4	—	8	—	14	—	10	—
White	1,416	—	1,458	—	1,512	—	1,287	—	1,522	—
Multiracial	256	—	299	—	265	—	184	—	205	—
Region of residence^d
Northeast	1,326	5.4	1,220	4.9	1,156	4.7	879	3.5	1,046	4.2
Midwest	944	3.2	925	3.2	969	3.3	740	2.5	893	3.0
South	4,065	7.7	3,923	7.3	3,817	7.1	2,985	5.5	3,707	6.8
West	926	2.9	989	3.0	981	3.0	825	2.5	938	2.8
U.S. dependent areas	94	5.6	81	5.0	83	5.0	46	2.7	82	4.8
Subtotal	7,355	5.2	7,138	5.0	7,006	4.9	5,475	3.8	6,666	4.6
Total	38,791	14.1	37,762	13.6	36,845	13.2	30,585	10.8	36,136	12.7

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^b Data include transgender and additional gender identity persons.
^c Hispanic/Latino persons can be of any race.
^d Data are based on residence at time of diagnosis of HIV infection.

Table 4a. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year of diagnosis and selected characteristics, 2017–2021—United States
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
Transgender woman^a
Age at diagnosis (yr)
13–14	0	0	0	0	1
15–19	67	48	44	34	58
20–24	164	175	180	156	227
25–29	174	195	177	212	172
30–34	114	98	138	127	167
35–39	59	72	63	49	77
40–44	31	33	42	35	51
45–49	22	22	19	32	25
50–54	8	6	16	19	12
55–59	7	6	8	6	12
60–64	5	4	4	5	8
≥ 65	0	2	1	1	1
Race/ethnicity
American Indian/Alaska Native	2	9	5	8	10
Asian	19	11	11	14	17
Black/African American	324	317	341	327	374
Hispanic/Latino^b	196	219	226	220	257
Native Hawaiian/other Pacific Islander	4	3	5	3	6
White	80	69	79	73	112
Multiracial	26	33	25	31	35
Exposure category^c
Sexual contact^d	592	596	616	611	716
Injection drug use^e	4	4	2	1	3
Sexual contact^d and injection drug use^e	40	53	58	44	56
Other^f	15	8	16	20	36
Region of residence^g
Northeast	104	117	105	111	110
Midwest	108	108	96	102	139
South	294	290	310	298	352
West	145	146	181	165	210
Subtotal	651	661	692	676	811
Transgender man^a
Age at diagnosis (yr)
13–14	0	0	0	0	1
15–19	3	2	0	1	6
20–24	7	9	11	12	8
25–29	16	18	18	10	17
30–34	1	9	13	8	13
35–39	2	4	1	6	6
40–44	0	4	0	2	2
45–49	2	1	2	1	0
50–54	0	1	0	1	1
55–59	1	0	0	0	1
60–64	0	0	0	0	0
≥ 65	0	0	0	0	1
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian	2	0	1	0	2
Black/African American	11	17	17	10	18
Hispanic/Latino^b	6	11	13	11	14
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	10	18	9	15	19
Multiracial	3	2	5	5	3
Exposure category^c
Sexual contact^d	27	40	35	30	47
Injection drug use^e	1	2	1	1	0
Sexual contact^d and injection drug use^e	1	3	3	5	1
Other^f	3	3	6	5	8
Region of residence^g
Northeast	5	7	6	9	9
Midwest	8	7	6	2	10
South	12	16	18	24	22
West	7	18	15	6	15
Subtotal	32	48	45	41	56
Additional gender identity^h
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	1	4	5	3	3
20–24	4	7	13	7	22
25–29	3	4	7	8	7
30–34	3	2	4	1	5
35–39	5	1	2	2	2
40–44	0	0	0	1	1
45–49	2	1	0	1	2
50–54	0	0	1	0	2
55–59	0	0	0	0	0
60–64	0	0	0	0	0
≥ 65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	1	0	0	0
Asian	1	2	0	1	0
Black/African American	7	7	11	10	12
Hispanic/Latino^b	7	4	7	5	14
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	3	3	9	6	15
Multiracial	0	2	5	1	3
Exposure category^c
Sexual contact^d	16	19	29	20	38
Injection drug use^e	0	0	0	0	0
Sexual contact^d and injection drug use^e	1	0	2	1	5
Other^f	1	0	1	2	1
Region of residence^g
Northeast	9	8	9	2	12
Midwest	3	4	10	6	8
South	6	5	9	7	9
West	0	2	4	8	15
Subtotal	18	19	32	23	44
Total	701	728	769	740	911

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Hispanic/Latino persons can be of any race.
^c Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^f Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^g Data are based on residence at time of diagnosis of HIV infection.
^h Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4b. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
Transgender woman^a
Age at diagnosis (yr)
13–14	0	0	0	0	1
15–19	67	48	44	34	58
20–24	165	176	181	158	227
25–29	175	196	178	212	172
30–34	114	99	138	128	167
35–39	59	73	63	49	77
40–44	31	33	42	35	52
45–49	22	22	19	32	25
50–54	8	6	16	19	12
55–59	7	6	8	6	12
60–64	5	4	4	5	8
≥ 65	0	2	1	1	1
Race/ethnicity
American Indian/Alaska Native	2	9	5	8	10
Asian	19	11	11	14	17
Black/African American	324	317	341	327	374
Hispanic/Latino^b	198	223	228	223	258
Native Hawaiian/other Pacific Islander	4	3	5	3	6
White	80	69	79	73	112
Multiracial	26	33	25	31	35
Exposure category^c
Sexual contact^d	594	600	618	614	717
Injection drug use^e	4	4	2	1	3
Sexual contact^d and injection drug use^e	40	53	58	44	56
Other^f	15	8	16	20	36
Region of residence^g
Northeast	104	117	105	111	110
Midwest	108	108	96	102	139
South	294	290	310	298	352
West	145	146	181	165	210
US dependent areas	2	4	2	3	1
Subtotal	653	665	694	679	812
Transgender man^a
Age at diagnosis (yr)
13–14	0	0	0	0	1
15–19	3	2	0	1	6
20–24	7	9	11	12	8
25–29	16	18	18	10	17
30–34	1	9	13	8	13
35–39	2	4	1	6	6
40–44	0	4	0	2	2
45–49	2	1	2	1	0
50–54	0	1	0	1	1
55–59	1	0	0	0	1
60–64	0	0	0	0	0
≥ 65	0	0	0	0	1
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian	2	0	1	0	2
Black/African American	11	17	17	10	18
Hispanic/Latino^b	6	11	13	11	14
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	10	18	9	15	19
Multiracial	3	2	5	5	3
Exposure category^c
Sexual contact^d	27	40	35	30	47
Injection drug use^e	1	2	1	1	0
Sexual contact^d and injection drug use^e	1	3	3	5	1
Other^f	3	3	6	5	8
Region of residence^g
Northeast	5	7	6	9	9
Midwest	8	7	6	2	10
South	12	16	18	24	22
West	7	18	15	6	15
US dependent areas	0	0	0	0	0
Subtotal	32	48	45	41	56
Additional gender identity^h
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	1	4	5	3	3
20–24	4	7	13	7	22
25–29	3	4	7	8	7
30–34	3	2	4	1	5
35–39	5	1	2	2	2
40–44	0	0	0	1	1
45–49	2	1	0	1	2
50–54	0	0	1	0	2
55–59	0	0	0	0	0
60–64	0	0	0	0	0
≥ 65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	1	0	0	0
Asian	1	2	0	1	0
Black/African American	7	7	11	10	12
Hispanic/Latino^b	7	4	7	5	14
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	3	3	9	6	15
Multiracial	0	2	5	1	3
Exposure category^c
Sexual contact^d	16	19	29	20	38
Injection drug use^e	0	0	0	0	0
Sexual contact^d and injection drug use^e	1	0	2	1	5
Other^f	1	0	1	2	1
Region of residence^g
Northeast	9	8	9	2	12
Midwest	3	4	10	6	8
South	6	5	9	7	9
West	0	2	4	8	15
US dependent areas	0	0	0	0	0
Subtotal	18	19	32	23	44
Total	703	732	771	743	912

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Hispanic/Latino persons can be of any race.
^c Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^f Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^g Data are based on residence at time of diagnosis of HIV infection.
^h Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 5a. Diagnoses of HIV infection among males, based on assigned sex at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2017–2021—United States
	Male-to-male sexual contact					Male-to-male sexual contact and injection drug use
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	2	7	6	5	10	0	0	0	0	0
20–24	19	24	25	19	19	3	2	3	5	1
25–29	29	21	25	25	32	5	7	5	5	1
30–34	15	19	15	18	26	6	4	1	3	6
35–39	15	8	18	13	21	0	2	3	5	4
40–44	10	7	6	12	10	2	1	0	2	1
45–49	6	7	7	6	6	1	2	1	0	1
50–54	8	6	7	10	8	0	0	1	1	2
55–59	2	3	3	5	3	0	0	0	0	0
60–64	2	0	1	1	5	1	0	0	0	0
≥ 65	1	3	0	2	2	1	0	0	0	0
Region of residence^a
Northeast	2	4	3	5	4	0	0	0	0	0
Midwest	10	13	8	9	19	3	4	1	5	6
South	23	16	37	33	41	9	2	3	0	1
West	73	71	65	70	76	6	13	10	15	8
Total	108	103	113	117	141	18	19	14	21	16
Asian
Age at diagnosis (yr)
13–14	0	1	0	0	0	0	0	0	0	0
15–19	25	23	19	17	21	0	0	0	0	0
20–24	147	105	94	58	82	2	0	2	1	1
25–29	151	163	126	120	122	4	5	3	4	4
30–34	111	117	93	89	113	6	2	6	3	4
35–39	88	71	73	49	72	1	3	1	0	4
40–44	74	62	41	45	47	0	1	1	2	1
45–49	64	57	51	40	39	2	0	1	0	1
50–54	34	22	34	22	39	0	0	0	0	0
55–59	21	21	16	13	23	0	0	0	0	1
60–64	10	11	8	11	8	0	0	0	0	0
≥ 65	7	10	8	9	6	0	0	0	0	0
Region of residence^a
Northeast	127	121	99	71	109	2	1	2	0	2
Midwest	73	65	53	53	56	0	0	1	1	3
South	153	169	140	100	151	1	2	4	1	4
West	380	307	270	247	256	12	9	7	10	8
Total	733	661	563	472	573	15	12	14	12	17
Black/African American
Age at diagnosis (yr)
13–14	4	7	7	2	2	0	1	0	0	0
15–19	853	808	793	604	685	12	10	10	12	9
20–24	2,512	2,409	2,378	2,072	2,343	45	52	41	41	30
25–29	2,459	2,486	2,335	1,967	2,067	75	84	87	58	50
30–34	1,334	1,266	1,424	1,447	1,636	51	50	65	53	62
35–39	752	742	741	655	778	37	29	39	26	37
40–44	434	447	456	384	423	21	18	21	16	24
45–49	351	352	333	266	288	14	12	17	8	14
50–54	324	311	283	236	232	25	17	18	6	6
55–59	205	203	204	194	228	11	9	9	7	6
60–64	111	99	111	93	122	5	6	6	3	3
≥ 65	66	76	81	54	75	5	4	2	2	2
Region of residence^a
Northeast	1,140	1,073	1,112	923	1,007	38	53	38	34	36
Midwest	1,500	1,458	1,408	1,304	1,393	50	54	44	37	41
South	5,955	5,853	5,835	5,033	5,659	161	142	178	119	131
West	811	820	790	714	820	54	43	55	41	36
Total	9,405	9,205	9,145	7,973	8,879	303	292	314	232	244
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	5	0	2	3	3	0	0	0	0	0
15–19	339	324	363	259	312	11	12	8	7	7
20–24	1,402	1,385	1,407	1,067	1,275	68	75	70	38	46
25–29	1,770	1,788	1,744	1,440	1,741	99	114	101	88	79
30–34	1,345	1,317	1,299	1,201	1,577	74	61	71	61	71
35–39	925	904	899	736	1,031	53	48	63	36	46
40–44	593	554	588	521	655	24	28	38	21	31
45–49	517	493	449	340	440	20	20	25	20	15
50–54	343	329	351	285	330	17	17	22	11	16
55–59	172	189	179	185	204	8	3	11	5	8
60–64	71	88	91	82	118	4	5	3	7	5
≥ 65	76	68	70	54	73	2	3	3	2	2
Region of residence^a
Northeast	1,300	1,177	1,172	939	1,124	44	59	62	31	34
Midwest	519	523	532	413	587	30	33	34	19	16
South	3,224	3,151	3,135	2,560	3,438	132	121	156	112	116
West	2,514	2,587	2,601	2,258	2,608	174	172	162	133	160
Total	7,556	7,438	7,441	6,170	7,757	379	385	414	295	325
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	1	3	1	2	5	0	0	0	1	0
20–24	7	5	6	6	3	0	2	0	0	1
25–29	7	9	16	10	15	1	2	0	1	0
30–34	7	10	9	7	9	0	1	1	1	2
35–39	2	8	7	6	10	1	0	1	1	0
40–44	5	2	4	6	7	0	0	0	0	0
45–49	1	2	0	1	3	0	0	0	1	0
50–54	1	1	3	2	4	0	0	0	0	0
55–59	0	4	1	1	1	0	0	0	0	0
60–64	0	1	1	0	2	0	0	0	0	0
≥ 65	0	1	0	0	1	0	0	0	0	0
Region of residence^a
Northeast	2	2	1	3	2	0	0	0	0	0
Midwest	3	1	4	3	6	0	0	0	1	0
South	6	8	10	6	16	0	0	0	0	0
West	21	34	33	28	35	2	5	2	4	3
Total	31	45	48	41	59	2	5	2	5	4
White
Age at diagnosis (yr)
13–14	1	0	1	0	0	0	0	0	0	0
15–19	160	166	129	119	106	12	11	13	3	3
20–24	905	782	707	583	603	91	71	81	54	52
25–29	1,181	1,099	1,076	896	1,006	175	188	167	126	119
30–34	865	942	863	826	1,009	128	147	147	112	173
35–39	718	650	648	525	718	100	122	116	108	120
40–44	489	509	448	434	547	64	59	67	52	100
45–49	606	546	461	395	426	62	51	55	46	55
50–54	669	530	499	435	465	38	44	38	32	42
55–59	436	429	459	404	434	24	27	33	24	21
60–64	243	248	236	202	263	17	6	14	10	19
≥ 65	181	213	184	181	180	11	7	10	4	11
Region of residence^a
Northeast	825	745	687	560	668	79	80	65	72	82
Midwest	1,202	1,082	959	923	1,081	107	136	150	100	142
South	2,795	2,741	2,605	2,201	2,620	319	302	309	225	284
West	1,632	1,545	1,459	1,318	1,389	217	217	220	174	207
Total	6,454	6,113	5,710	5,002	5,758	721	734	742	570	714
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	64	48	51	44	54	3	2	2	0	0
20–24	245	221	189	138	149	13	12	6	9	6
25–29	272	218	218	168	145	15	30	22	13	14
30–34	162	138	136	102	125	14	14	27	6	16
35–39	94	95	83	74	65	14	13	8	7	8
40–44	59	55	58	51	46	5	2	11	8	1
45–49	59	47	40	43	31	5	5	1	5	4
50–54	59	36	20	31	32	6	4	2	2	1
55–59	24	18	39	16	23	4	0	1	0	2
60–64	13	12	11	8	6	0	0	1	1	0
≥ 65	7	11	8	11	13	0	1	1	0	1
Region of residence^a
Northeast	177	151	150	108	111	12	11	8	5	6
Midwest	167	124	101	100	103	11	16	14	11	16
South	504	452	436	354	360	40	30	43	23	20
West	209	172	164	124	115	17	28	16	12	12
Total	1,057	898	852	685	688	79	84	81	51	54
Total
Age at diagnosis (yr)
13–14	10	8	10	4	5	0	1	0	0	1
15–19	1,444	1,377	1,362	1,049	1,193	39	37	34	23	19
20–24	5,237	4,931	4,805	3,944	4,473	222	214	203	147	137
25–29	5,870	5,784	5,540	4,623	5,128	372	430	384	295	268
30–34	3,838	3,807	3,838	3,689	4,496	278	280	318	240	334
35–39	2,592	2,479	2,468	2,059	2,694	206	217	231	182	218
40–44	1,665	1,635	1,600	1,453	1,735	116	109	138	102	159
45–49	1,605	1,505	1,341	1,090	1,232	105	91	99	80	91
50–54	1,438	1,235	1,197	1,023	1,109	85	82	80	53	67
55–59	860	865	900	818	914	47	40	54	36	38
60–64	450	458	459	397	525	28	18	25	20	28
≥ 65	338	380	350	311	350	19	14	17	8	16
Region of residence^a
Northeast	3,572	3,273	3,225	2,609	3,025	175	204	175	142	160
Midwest	3,474	3,266	3,064	2,805	3,244	201	243	244	176	225
South	12,660	12,389	12,199	10,288	12,286	661	598	691	480	555
West	5,639	5,536	5,382	4,758	5,300	480	487	472	387	434
Total	25,345	24,464	23,870	20,460	23,855	1,517	1,531	1,581	1,185	1,373

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

^a Data are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 5b. Diagnoses of HIV infection among males, based on assigned sex at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
	Male-to-male sexual contact					Male-to-male sexual contact and injection drug use
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	2	7	6	5	10	0	0	0	0	0
20–24	19	24	25	19	19	3	2	3	5	1
25–29	29	21	25	25	32	5	7	5	5	1
30–34	15	19	15	18	26	6	4	1	3	6
35–39	15	8	18	13	21	0	2	3	5	4
40–44	10	7	6	12	10	2	1	0	2	1
45–49	6	7	7	6	6	1	2	1	0	1
50–54	8	6	7	10	8	0	0	1	1	2
55–59	2	3	3	5	3	0	0	0	0	0
60–64	2	0	1	1	5	1	0	0	0	0
≥ 65	1	3	0	2	2	1	0	0	0	0
Region of residence^a
Northeast	2	4	3	5	4	0	0	0	0	0
Midwest	10	13	8	9	19	3	4	1	5	6
South	23	16	37	33	41	9	2	3	0	1
West	73	71	65	70	76	6	13	10	15	8
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	108	103	113	117	141	18	19	14	21	16
Asian
Age at diagnosis (yr)
13–14	0	1	0	0	0	0	0	0	0	0
15–19	25	23	19	17	21	0	0	0	0	0
20–24	147	105	94	58	82	2	0	2	1	1
25–29	151	164	129	120	123	4	5	4	4	4
30–34	113	119	94	89	113	6	2	6	3	4
35–39	89	71	74	49	72	1	3	1	0	4
40–44	74	62	41	45	47	0	1	1	2	1
45–49	64	57	51	40	39	2	0	1	0	1
50–54	34	22	35	22	39	0	0	0	0	0
55–59	21	21	16	13	23	0	0	0	0	1
60–64	10	11	8	11	8	0	0	0	0	0
≥ 65	7	10	8	9	6	0	0	0	0	0
Region of residence^a
Northeast	127	121	99	71	109	2	1	2	0	2
Midwest	73	65	53	53	56	0	0	1	1	3
South	153	169	140	100	151	1	2	4	1	4
West	380	307	270	247	256	12	9	7	10	8
U.S. dependent areas	3	4	5	0	1	0	0	1	0	0
Total	736	665	568	472	574	15	12	15	12	17
Black/African American
Age at diagnosis (yr)
13–14	4	7	7	2	2	0	1	0	0	0
15–19	853	808	793	606	685	12	10	10	12	9
20–24	2,512	2,410	2,379	2,072	2,344	45	52	41	41	30
25–29	2,459	2,488	2,336	1,967	2,067	75	84	87	58	50
30–34	1,334	1,267	1,424	1,447	1,637	51	50	65	53	62
35–39	752	742	741	655	778	37	29	39	26	37
40–44	435	447	456	384	423	21	18	21	16	24
45–49	351	352	333	266	288	14	12	17	8	14
50–54	324	311	283	237	232	25	17	18	6	6
55–59	205	203	204	194	229	11	9	9	7	6
60–64	111	99	111	93	122	5	6	6	3	3
≥ 65	66	76	81	54	75	5	4	2	2	2
Region of residence^a
Northeast	1,140	1,073	1,112	923	1,007	38	53	38	34	36
Midwest	1,500	1,458	1,408	1,304	1,393	50	54	44	37	41
South	5,955	5,853	5,835	5,033	5,659	161	142	178	119	131
West	811	820	790	714	820	54	43	55	41	36
U.S. dependent areas	2	4	2	3	3	0	0	0	0	0
Total	9,407	9,209	9,147	7,976	8,883	303	292	314	232	244
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	5	0	2	3	3	0	0	0	0	0
15–19	347	339	369	265	314	11	12	8	7	8
20–24	1,451	1,437	1,453	1,103	1,316	70	76	73	39	46
25–29	1,811	1,841	1,790	1,474	1,812	103	117	102	90	79
30–34	1,382	1,353	1,336	1,231	1,609	75	64	73	61	71
35–39	948	926	923	763	1,055	55	49	64	37	46
40–44	609	578	601	533	677	24	28	38	21	32
45–49	534	516	462	352	453	22	20	26	20	15
50–54	365	346	366	304	349	17	17	22	11	16
55–59	183	199	191	193	213	8	4	12	5	8
60–64	75	96	100	88	123	4	6	4	7	5
≥ 65	80	71	74	56	77	2	4	4	2	2
Region of residence^a
Northeast	1,300	1,177	1,172	939	1,124	44	59	62	31	34
Midwest	519	523	532	413	587	30	33	34	19	16
South	3,224	3,151	3,135	2,560	3,438	132	121	156	112	116
West	2,514	2,587	2,601	2,258	2,608	174	172	162	133	160
U.S. dependent areas	232	263	226	195	243	12	11	11	5	2
Total	7,788	7,701	7,666	6,366	8,000	391	397	425	299	327
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	1	3	1	2	5	0	0	0	1	0
20–24	7	5	6	6	3	0	2	0	0	1
25–29	7	9	16	10	15	1	2	1	1	0
30–34	7	10	9	8	9	0	1	1	1	2
35–39	2	9	7	6	10	1	0	1	1	0
40–44	5	2	5	6	7	0	0	0	0	0
45–49	1	2	0	1	3	0	0	0	1	0
50–54	2	1	4	2	4	0	0	0	0	0
55–59	1	4	1	1	1	0	0	0	0	0
60–64	0	1	1	0	2	0	0	0	0	0
≥ 65	0	1	0	0	1	0	0	0	0	0
Region of residence^a
Northeast	2	2	1	3	2	0	0	0	0	0
Midwest	3	1	4	3	6	0	0	0	1	0
South	6	8	10	6	16	0	0	0	0	0
West	21	34	33	28	35	2	5	2	4	3
U.S. dependent areas	2	2	2	1	0	0	0	1	0	0
Total	33	46	50	42	59	2	5	3	5	4
White
Age at diagnosis (yr)
13–14	1	0	1	0	0	0	0	0	0	0
15–19	160	166	129	119	106	12	11	13	3	3
20–24	905	782	707	583	603	91	71	81	54	52
25–29	1,181	1,099	1,076	896	1,007	175	188	167	126	119
30–34	865	942	865	826	1,009	128	147	147	112	173
35–39	720	651	648	525	719	100	122	116	108	120
40–44	489	510	448	434	547	64	59	67	52	100
45–49	606	547	461	396	427	62	51	55	46	55
50–54	670	532	500	435	465	38	44	38	32	42
55–59	436	430	459	404	435	24	27	33	24	21
60–64	243	248	237	202	264	17	6	14	10	19
≥ 65	181	213	185	181	180	11	7	10	4	11
Region of residence^a
Northeast	825	745	687	560	668	79	80	65	72	82
Midwest	1,202	1,082	959	923	1,081	107	136	150	100	142
South	2,795	2,741	2,605	2,201	2,620	319	302	309	225	284
West	1,632	1,545	1,459	1,318	1,389	217	217	220	174	207
U.S. dependent areas	3	6	4	1	5	0	0	0	0	0
Total	6,457	6,119	5,714	5,002	5,762	721	734	742	570	714
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	64	48	51	44	54	3	2	2	0	0
20–24	245	221	189	138	149	13	12	6	9	6
25–29	272	218	218	168	145	15	30	22	13	14
30–34	162	138	136	102	125	14	14	27	6	16
35–39	94	95	83	74	65	14	13	8	7	8
40–44	59	55	58	51	46	5	2	11	8	1
45–49	59	47	40	43	31	5	5	1	5	4
50–54	59	36	20	31	32	6	4	2	2	1
55–59	24	18	39	16	23	4	0	1	0	2
60–64	13	12	11	8	6	0	0	1	1	0
≥ 65	7	11	8	11	13	0	1	1	0	1
Region of residence^a
Northeast	177	151	150	108	111	12	11	8	5	6
Midwest	167	124	101	100	103	11	16	14	11	16
South	504	452	436	354	360	40	30	43	23	20
West	209	172	164	124	115	17	28	16	12	12
U.S. dependent areas	1	0	0	0	0	0	0	0	0	0
Total	1,058	898	852	685	688	79	84	81	51	54
Total
Age at diagnosis (yr)
13–14	10	8	10	4	5	0	1	0	0	1
15–19	1,452	1,392	1,368	1,057	1,195	39	37	34	23	20
20–24	5,286	4,983	4,852	3,980	4,515	224	215	206	148	137
25–29	5,910	5,840	5,590	4,658	5,201	376	433	387	297	268
30–34	3,877	3,846	3,878	3,721	4,529	279	283	320	240	334
35–39	2,619	2,503	2,493	2,086	2,719	208	218	232	183	218
40–44	1,682	1,661	1,615	1,466	1,757	116	109	138	102	159
45–49	1,622	1,529	1,354	1,103	1,246	107	91	100	81	91
50–54	1,461	1,255	1,214	1,042	1,129	85	82	80	53	67
55–59	872	878	913	827	925	47	41	55	36	38
60–64	454	466	469	403	530	28	19	25	20	28
≥ 65	343	383	356	313	355	19	15	18	8	16
Region of residence^a
Northeast	3,572	3,273	3,225	2,609	3,025	175	204	175	142	160
Midwest	3,474	3,266	3,064	2,805	3,244	201	243	244	176	225
South	12,660	12,389	12,199	10,288	12,286	661	598	691	480	555
West	5,639	5,536	5,382	4,758	5,300	480	487	472	387	434
U.S. dependent areas	242	278	240	200	252	12	11	13	5	2
Total	25,587	24,742	24,110	20,660	24,107	1,529	1,542	1,594	1,190	1,375

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

^a Data are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, assigned sex at birth, race/ethnicity, and selected characteristics, 2017–2021—United States
	Male sex at birth					Female sex at birth
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	0	0	0	1
20–24	0	0	2	1	0	1	0	2	0	1
25–29	6	1	0	0	3	2	3	1	5	5
30–34	3	3	2	4	1	2	2	2	4	4
35–39	0	0	3	1	0	2	4	6	4	2
40–44	1	0	3	0	2	2	1	2	1	0
45–49	0	1	1	0	2	2	2	1	2	2
50–54	3	2	1	2	0	3	2	2	0	3
55–59	0	0	0	0	0	0	1	0	1	1
60–64	1	0	0	0	0	1	1	0	0	0
≥ 65	1	0	0	0	0	1	0	1	0	0
Region of residence^a
Northeast	1	0	0	0	0	1	0	0	0	0
Midwest	2	3	3	2	3	1	3	5	8	6
South	2	1	3	4	3	4	6	6	1	1
West	11	6	8	2	4	9	6	7	8	10
Total	17	9	14	9	10	16	15	18	17	17
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	1	0	0	0	0	0	0	0	0
25–29	1	0	1	1	0	2	0	0	0	2
30–34	1	3	0	2	2	0	2	2	2	0
35–39	1	0	3	1	2	1	1	1	1	0
40–44	3	2	2	2	2	0	0	1	0	1
45–49	2	2	2	2	2	0	0	1	0	0
50–54	1	1	3	2	2	1	0	0	1	1
55–59	0	1	1	0	1	0	1	0	0	0
60–64	0	1	1	1	2	1	1	0	0	0
≥ 65	0	1	0	1	0	0	0	0	0	0
Region of residence^a
Northeast	4	5	3	2	2	1	2	2	1	1
Midwest	0	1	3	2	4	0	0	0	0	1
South	2	4	2	1	1	1	2	1	2	2
West	4	1	6	8	6	3	2	3	2	2
Total	10	11	14	13	14	5	5	6	5	6
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	5	4	3	2	2	12	9	7	8	5
20–24	19	22	20	18	25	35	23	32	18	24
25–29	34	45	50	33	33	36	30	45	37	36
30–34	49	43	58	42	50	39	42	42	36	38
35–39	44	53	42	33	48	39	36	42	31	37
40–44	30	35	39	28	43	42	29	39	20	33
45–49	42	41	31	30	30	41	32	37	29	29
50–54	42	49	37	29	33	40	40	34	25	29
55–59	55	50	39	37	43	33	38	33	30	31
60–64	32	36	41	23	34	25	24	27	18	19
≥ 65	33	35	32	28	31	19	16	20	10	19
Region of residence^a
Northeast	120	118	107	85	94	95	76	97	52	68
Midwest	61	57	52	43	47	60	48	50	43	53
South	173	195	190	149	191	172	158	171	132	147
West	30	43	41	24	39	35	35	40	34	32
Total	385	413	389	301	371	361	318	358	260	300
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	1	0
15–19	4	3	1	2	1	5	2	6	3	3
20–24	22	24	17	14	21	20	24	19	11	12
25–29	40	30	46	39	38	21	21	23	19	25
30–34	59	64	46	34	60	35	27	22	30	26
35–39	45	49	48	39	46	24	29	34	26	26
40–44	42	35	35	40	33	18	16	13	14	18
45–49	38	35	23	26	30	15	20	17	11	13
50–54	40	38	28	24	26	13	15	18	9	14
55–59	23	26	25	14	20	9	10	10	10	12
60–64	12	15	13	14	12	7	9	7	9	6
≥ 65	12	8	13	13	11	4	5	5	4	6
Region of residence^a
Northeast	115	103	89	69	69	50	57	47	38	38
Midwest	16	14	11	14	26	10	10	14	7	7
South	95	96	82	77	86	53	52	53	38	50
West	112	114	112	99	119	58	58	60	62	65
Total	338	327	294	260	299	171	177	173	146	161
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0
25–29	0	0	1	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	1
35–39	0	0	0	1	0	0	0	0	0	1
40–44	0	0	0	0	0	0	0	0	0	0
45–49	0	1	0	0	0	0	0	0	1	0
50–54	1	0	0	0	0	0	0	0	0	1
55–59	0	0	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	1	0
≥ 65	0	0	0	0	1	0	0	0	0	0
Region of residence^a
Northeast	0	0	0	0	0	0	0	0	0	0
Midwest	0	0	1	1	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	1
West	1	1	0	0	1	0	0	0	1	2
Total	1	1	1	1	1	0	0	0	2	3
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	3	4	0	3	2	10	8	6	2	7
20–24	35	34	42	19	28	49	48	44	18	32
25–29	82	96	104	80	103	90	85	90	76	81
30–34	90	106	112	119	139	100	98	107	86	112
35–39	75	109	99	115	139	81	96	98	71	109
40–44	46	63	71	66	91	52	73	78	46	59
45–49	57	50	69	51	56	39	46	56	39	50
50–54	37	50	43	33	54	44	44	41	38	49
55–59	37	32	45	34	31	32	28	36	34	27
60–64	18	22	16	14	20	10	11	14	16	17
≥ 65	18	8	9	10	15	6	7	6	8	10
Region of residence^a
Northeast	94	110	93	102	113	90	92	82	56	72
Midwest	93	117	106	91	122	93	111	100	64	110
South	195	214	272	247	316	236	228	282	230	277
West	115	132	138	104	128	93	113	110	85	93
Total	497	574	610	543	679	513	543	574	434	553
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	2	3	1	0	2
20–24	2	5	4	6	3	6	10	3	2	3
25–29	8	5	4	5	5	8	11	11	6	5
30–34	6	5	13	10	11	4	7	5	4	5
35–39	4	3	3	10	5	6	6	12	4	5
40–44	5	4	3	1	7	5	5	7	5	4
45–49	7	3	3	4	1	4	8	6	5	3
50–54	5	7	5	2	4	4	5	4	1	4
55–59	3	4	2	3	4	3	2	2	1	2
60–64	3	3	1	2	1	1	3	1	1	1
≥ 65	2	1	3	0	0	0	2	2	1	0
Region of residence^a
Northeast	13	7	17	5	6	12	11	10	4	5
Midwest	11	7	8	9	6	6	9	11	7	5
South	12	16	12	22	20	18	28	25	14	18
West	8	11	5	8	9	7	13	8	5	6
Total	44	41	42	43	41	44	60	54	30	35
Total
Age at diagnosis (yr)
13–14	1	0	0	0	0	0	0	0	1	1
15–19	13	12	4	7	7	29	21	20	13	17
20–24	77	87	84	58	77	112	104	100	50	73
25–29	171	177	207	159	183	159	150	170	143	155
30–34	208	224	231	211	264	179	178	180	162	185
35–39	170	215	198	201	240	153	171	193	136	180
40–44	126	139	153	137	178	119	124	139	86	115
45–49	146	132	129	113	121	102	107	117	87	97
50–54	128	147	117	92	119	105	106	99	73	101
55–59	118	113	111	87	98	77	78	82	75	74
60–64	67	76	72	54	69	44	47	49	45	43
≥ 65	65	54	57	52	60	30	30	34	22	35
Region of residence^a
Northeast	346	343	308	263	283	249	238	237	151	185
Midwest	184	199	184	162	209	170	180	180	129	183
South	479	527	560	499	617	485	473	538	417	496
West	282	307	310	245	307	205	226	228	197	211
Total	1,291	1,376	1,362	1,169	1,415	1,109	1,117	1,182	895	1,075

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, assigned sex at birth, race/ethnicity, and selected characteristics, 2017–2021—United States and 6 dependent areas
	Male sex at birth					Female sex at birth
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	0	0	0	1
20–24	0	0	2	1	0	1	0	2	0	1
25–29	6	1	0	0	3	2	3	1	5	5
30–34	3	3	2	4	1	2	2	2	4	4
35–39	0	0	3	1	0	2	4	6	4	2
40–44	1	0	3	0	2	2	1	2	1	0
45–49	0	1	1	0	2	2	2	1	2	2
50–54	3	2	1	2	0	3	2	2	0	3
55–59	0	0	0	0	0	0	1	0	1	1
60–64	1	0	0	0	0	1	1	0	0	0
≥ 65	1	0	0	0	0	1	0	1	0	0
Region of residence^a
Northeast	1	0	0	0	0	1	0	0	0	0
Midwest	2	3	3	2	3	1	3	5	8	6
South	2	1	3	4	3	4	6	6	1	1
West	11	6	8	2	4	9	6	7	8	10
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	17	9	14	9	10	16	15	18	17	17
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	1	0	0	0	0	0	0	0	0
25–29	1	0	1	1	0	2	0	0	0	2
30–34	1	3	0	2	2	0	2	2	2	0
35–39	1	0	3	1	2	1	1	1	1	0
40–44	3	2	2	2	2	0	0	1	0	1
45–49	2	2	2	2	2	0	0	1	0	0
50–54	1	1	3	2	2	1	0	0	1	1
55–59	0	1	1	0	1	0	1	0	0	0
60–64	0	1	1	1	2	1	1	0	0	0
≥ 65	0	1	0	1	0	0	0	0	0	0
Region of residence^a
Northeast	4	5	3	2	2	1	2	2	1	1
Midwest	0	1	3	2	4	0	0	0	0	1
South	2	4	2	1	1	1	2	1	2	2
West	4	1	6	8	6	3	2	3	2	2
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	10	11	14	13	14	5	5	6	5	6
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	5	4	3	2	2	12	9	7	8	5
20–24	19	22	20	18	25	35	23	32	18	24
25–29	34	45	50	33	33	36	30	45	37	36
30–34	49	43	58	42	50	39	42	42	36	38
35–39	44	53	42	33	48	39	36	42	31	37
40–44	30	35	39	28	43	42	29	39	21	33
45–49	42	41	31	30	30	41	32	37	29	29
50–54	42	49	37	29	33	40	40	34	25	29
55–59	55	51	40	37	43	33	38	33	30	31
60–64	32	36	42	23	34	25	24	27	18	19
≥ 65	33	36	32	28	31	19	16	20	10	19
Region of residence^a
Northeast	120	118	107	85	94	95	76	97	52	68
Midwest	61	57	52	43	47	60	48	50	43	53
South	173	195	190	149	191	172	158	171	132	147
West	30	43	41	24	39	35	35	40	34	32
U.S. dependent areas	0	2	3	1	1	0	0	0	1	0
Total	385	415	391	301	373	362	318	358	261	300
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	1	0
15–19	5	3	1	2	1	5	2	6	3	3
20–24	23	24	17	14	21	20	25	19	11	12
25–29	43	32	46	39	40	21	21	23	19	25
30–34	64	67	47	37	61	35	28	22	30	27
35–39	46	50	52	42	49	26	29	35	26	26
40–44	44	39	39	45	38	18	16	13	15	18
45–49	41	38	24	28	32	18	20	19	11	13
50–54	48	43	30	26	28	14	15	19	10	14
55–59	27	27	26	16	21	10	10	11	10	12
60–64	16	17	15	15	15	8	9	7	9	6
≥ 65	15	10	17	14	13	4	5	5	5	6
Region of residence^a
Northeast	115	103	89	69	69	50	57	47	38	38
Midwest	16	14	11	14	26	10	10	14	7	7
South	95	96	82	77	86	53	52	53	38	50
West	112	114	112	99	119	58	58	60	62	65
U.S. dependent areas	35	23	19	19	19	9	3	5	3	2
Total	372	350	313	278	318	179	179	178	149	162
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0
25–29	0	0	1	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	1
35–39	0	0	0	1	0	0	0	0	0	1
40–44	0	0	0	0	0	0	0	0	0	0
45–49	0	1	0	0	0	0	0	0	1	0
50–54	1	0	0	0	0	0	0	0	0	1
55–59	0	0	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	1	0
≥ 65	0	0	0	0	1	0	0	0	0	0
Region of residence^a
Northeast	0	0	0	0	0	0	0	0	0	0
Midwest	0	0	1	1	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	1
West	1	1	0	0	1	0	0	0	1	2
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	1	2	1	1	1	0	0	0	2	3
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	3	4	0	3	2	10	8	6	2	7
20–24	35	34	42	19	28	49	48	44	18	32
25–29	82	96	104	80	103	90	85	90	76	81
30–34	90	106	112	119	139	100	98	107	86	112
35–39	75	109	99	115	139	81	96	98	71	109
40–44	46	63	71	66	91	52	73	78	46	59
45–49	57	50	69	52	57	39	46	56	39	50
50–54	37	50	43	33	54	44	44	41	38	49
55–59	37	32	45	34	31	32	28	36	34	27
60–64	18	22	16	14	20	10	11	14	16	17
≥ 65	18	8	9	10	15	6	7	6	8	10
Region of residence^a
Northeast	94	110	93	102	113	90	92	82	56	72
Midwest	93	117	106	91	122	93	111	100	64	110
South	195	214	272	247	316	236	228	282	230	277
West	115	132	138	104	128	93	113	110	85	93
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	497	574	610	543	679	513	543	574	434	553
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	2	3	1	0	2
20–24	2	5	4	6	3	6	10	3	2	3
25–29	8	5	4	5	5	8	11	11	6	5
30–34	6	5	13	10	11	4	7	5	4	5
35–39	5	3	3	10	5	6	6	12	4	5
40–44	5	4	3	1	7	5	5	7	5	4
45–49	7	3	3	4	1	4	8	6	5	3
50–54	5	7	5	2	4	4	5	4	1	4
55–59	3	4	2	3	4	3	2	2	1	2
60–64	3	3	1	2	1	1	3	1	1	1
≥ 65	2	1	3	0	0	0	2	2	1	0
Region of residence^a
Northeast	13	7	17	5	6	12	11	10	4	5
Midwest	11	7	8	9	6	6	9	11	7	5
South	12	16	12	22	20	18	28	25	14	18
West	8	11	5	8	9	7	13	8	5	6
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	44	41	42	43	41	44	60	54	30	35
Total
Age at diagnosis (yr)
13–14	1	0	0	0	0	0	0	0	1	1
15–19	14	12	4	7	7	29	21	20	13	17
20–24	78	87	84	58	77	112	105	100	50	73
25–29	173	179	207	159	184	159	150	170	143	155
30–34	213	227	232	214	264	180	179	180	162	186
35–39	171	216	202	203	242	155	171	194	136	180
40–44	129	143	157	142	182	119	124	139	87	115
45–49	149	135	130	115	123	106	108	119	88	97
50–54	137	152	119	93	122	106	106	100	74	102
55–59	123	115	113	90	100	78	78	83	76	74
60–64	71	78	75	56	72	45	48	50	45	43
≥ 65	69	56	61	53	61	30	30	34	23	36
Region of residence^a
Northeast	346	343	308	263	283	249	238	237	151	185
Midwest	184	199	184	162	209	170	180	180	129	183
South	479	527	560	499	617	485	473	538	417	496
West	282	307	310	245	307	205	226	228	197	211
U.S. dependent areas	35	25	22	20	20	9	3	5	4	2
Total	1,325	1,401	1,385	1,189	1,436	1,118	1,120	1,188	898	1,076

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, assigned sex at birth, race/ethnicity, and selected characteristics, 2017–2021—United States
	Male sex at birth					Female sex at birth
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	1	1	0	1
20–24	0	1	2	0	0	3	1	2	0	0
25–29	0	1	0	0	4	5	1	2	1	5
30–34	2	1	1	0	1	2	1	3	5	5
35–39	3	1	1	0	1	4	2	6	6	5
40–44	0	0	2	0	1	3	3	5	5	2
45–49	0	0	0	0	0	5	2	3	1	5
50–54	0	0	1	2	2	4	2	2	1	6
55–59	1	2	1	0	1	1	3	1	2	1
60–64	0	0	0	0	0	2	0	1	1	0
≥ 65	0	0	0	0	0	0	0	1	1	1
Region of residence^a
Northeast	0	1	0	0	1	0	0	0	1	0
Midwest	0	2	2	0	2	3	1	9	4	10
South	3	3	6	1	3	5	7	5	7	7
West	4	3	1	1	5	20	7	11	11	12
Total	7	8	9	3	11	27	15	25	23	29
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	1	0	2	0	1	1	1
20–24	2	5	0	1	3	5	7	6	2	8
25–29	3	2	3	1	4	17	15	10	12	9
30–34	4	7	2	2	2	8	16	16	13	11
35–39	10	7	2	4	7	23	10	16	14	12
40–44	3	10	5	3	6	11	13	7	3	18
45–49	5	6	4	3	3	12	8	15	8	3
50–54	2	6	6	4	6	12	8	4	8	11
55–59	2	3	3	4	4	8	8	8	6	3
60–64	4	5	3	2	3	6	5	7	7	5
≥ 65	3	6	3	6	4	4	7	3	3	6
Region of residence^a
Northeast	8	13	13	4	12	15	26	13	11	14
Midwest	6	2	1	3	3	19	5	11	10	11
South	11	22	11	13	18	30	27	29	21	32
West	13	18	7	9	7	45	38	38	35	28
Total	38	55	32	29	40	108	96	92	77	85
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	3	3	4	3	5
15–19	23	32	26	18	18	137	131	95	75	97
20–24	123	108	112	85	95	401	391	375	281	333
25–29	197	225	170	151	167	516	473	440	364	413
30–34	197	229	184	156	201	533	461	458	390	451
35–39	219	207	180	142	185	469	452	424	317	428
40–44	185	165	164	139	162	405	424	374	278	366
45–49	187	169	193	120	138	393	360	328	268	323
50–54	199	196	169	110	135	345	325	318	215	267
55–59	187	159	158	126	144	293	300	272	196	254
60–64	124	100	131	88	123	196	172	190	137	154
≥ 65	112	106	119	88	102	165	129	155	88	118
Region of residence^a
Northeast	310	251	243	185	249	633	555	521	391	486
Midwest	191	202	187	135	141	499	478	475	362	409
South	1,186	1,164	1,108	852	1,012	2,485	2,317	2,187	1,666	2,085
West	65	79	68	52	68	237	271	250	193	228
Total	1,752	1,695	1,606	1,225	1,470	3,853	3,621	3,433	2,612	3,207
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	1	1	5	4	0	1
15–19	8	6	10	2	4	38	32	33	30	36
20–24	27	29	25	30	30	114	94	112	97	95
25–29	68	58	75	49	61	141	131	142	98	137
30–34	74	91	65	44	64	128	129	147	100	131
35–39	78	83	72	63	74	127	143	113	109	145
40–44	80	70	70	41	73	104	106	113	91	119
45–49	54	75	57	38	49	119	107	96	70	111
50–54	53	59	51	52	54	84	107	89	71	83
55–59	37	46	39	27	40	71	68	63	51	71
60–64	31	22	33	23	28	40	46	46	33	36
≥ 65	27	33	21	19	28	38	44	39	22	33
Region of residence^a
Northeast	140	139	106	83	133	262	246	228	195	223
Midwest	31	33	33	18	27	63	55	70	45	60
South	272	314	293	221	257	454	469	455	353	468
West	93	86	83	65	89	226	240	245	178	246
Total	536	572	516	387	506	1,005	1,010	997	771	997
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	0	1	1	1	0
20–24	0	0	0	0	0	0	0	0	1	1
25–29	1	0	1	0	0	2	0	1	2	0
30–34	1	1	0	1	0	3	2	1	1	1
35–39	0	0	0	1	0	2	0	2	1	1
40–44	1	0	0	0	0	0	0	1	1	2
45–49	1	0	0	0	0	0	0	0	1	0
50–54	0	0	0	0	0	0	1	1	1	2
55–59	0	0	0	0	1	0	0	0	2	0
60–64	0	0	0	0	0	0	0	0	1	0
≥ 65	1	0	0	0	0	0	0	0	0	0
Region of residence^a
Northeast	1	0	0	0	0	1	1	0	1	2
Midwest	0	0	0	0	0	0	0	4	0	0
South	1	1	0	0	1	2	0	1	4	1
West	2	0	1	2	1	4	3	2	8	4
Total	5	2	1	2	3	7	4	7	12	7
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	1	0	0	1
15–19	5	3	3	1	3	26	30	31	21	33
20–24	15	19	20	15	20	93	89	90	96	78
25–29	48	47	50	31	44	110	121	127	115	92
30–34	50	58	39	40	41	124	123	123	113	142
35–39	45	51	43	37	49	105	111	120	105	128
40–44	51	42	46	31	45	83	102	95	89	133
45–49	52	54	53	41	35	106	106	105	103	98
50–54	63	44	49	38	45	95	92	91	69	90
55–59	49	51	45	35	38	93	71	81	77	89
60–64	37	38	30	27	27	38	37	47	30	42
≥ 65	34	31	25	27	32	25	25	22	30	37
Region of residence^a
Northeast	82	79	62	65	63	115	104	107	98	95
Midwest	49	54	60	52	51	147	160	177	147	189
South	240	240	214	167	213	485	486	481	421	503
West	76	65	67	40	53	151	160	167	181	174
Total	447	438	404	324	379	898	909	932	847	962
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	0	0	0	0
15–19	1	1	1	1	1	9	13	12	10	3
20–24	5	5	4	4	2	29	26	27	23	18
25–29	12	11	8	1	5	24	44	38	29	27
30–34	14	14	11	5	7	31	38	25	20	26
35–39	13	5	7	4	7	32	30	23	16	27
40–44	14	5	10	5	8	15	17	22	11	17
45–49	10	8	8	6	6	25	28	22	12	13
50–54	6	10	8	5	6	16	14	19	10	14
55–59	8	4	8	3	4	15	9	7	9	11
60–64	9	3	3	2	3	4	12	8	10	6
≥ 65	6	4	8	1	3	7	8	7	3	7
Region of residence^a
Northeast	22	24	23	8	11	43	43	41	24	31
Midwest	12	9	14	5	12	31	34	33	30	21
South	56	34	34	20	26	106	127	108	86	96
West	8	3	5	3	2	27	33	29	13	21
Total	97	69	76	36	52	207	237	210	153	169
Total
Age at diagnosis (yr)
13–14	0	0	0	0	1	6	8	8	3	6
15–19	38	44	41	24	27	211	208	174	137	171
20–24	171	167	163	136	150	646	607	611	499	532
25–29	327	344	307	233	285	815	784	760	620	682
30–34	342	401	302	249	316	828	770	773	643	766
35–39	368	354	304	251	321	761	749	704	569	745
40–44	333	292	296	219	294	621	665	617	477	656
45–49	308	312	315	208	231	658	611	569	463	552
50–54	323	314	284	210	247	555	548	523	375	472
55–59	284	264	254	195	232	480	459	432	343	428
60–64	205	168	200	141	185	287	271	297	219	243
≥ 65	183	179	176	140	170	238	213	227	148	202
Region of residence^a
Northeast	564	506	448	344	469	1,068	974	910	721	851
Midwest	289	301	297	214	237	761	733	778	598	700
South	1,768	1,778	1,666	1,275	1,529	3,567	3,433	3,266	2,556	3,192
West	261	253	232	173	224	710	751	742	619	713
Total	2,882	2,839	2,643	2,006	2,460	6,106	5,892	5,695	4,494	5,456

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified heterosexual contact include transgender and additional gender identity persons. Includes persons who have ever had heterosexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs). Excludes men who have ever had sexual contact with both men and women.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, assigned sex at birth, race/ethnicity and selected characteristics, 2017–2021—United States and 6 dependent areas
	Male sex at birth					Female sex at birth
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	1	1	0	1
20–24	0	1	2	0	0	3	1	2	0	0
25–29	0	1	0	0	4	5	1	2	1	5
30–34	2	1	1	0	1	2	1	3	5	5
35–39	3	1	1	0	1	4	2	6	6	5
40–44	0	0	2	0	1	3	3	5	5	2
45–49	0	0	0	0	0	5	2	3	1	5
50–54	0	0	1	2	2	4	2	2	1	6
55–59	1	2	1	0	1	1	3	1	2	1
60–64	0	0	0	0	0	2	0	1	1	0
≥ 65	0	0	0	0	0	0	0	1	1	1
Region of residence^a
Northeast	0	1	0	0	1	0	0	0	1	0
Midwest	0	2	2	0	2	3	1	9	4	10
South	3	3	6	1	3	5	7	5	7	7
West	4	3	1	1	5	20	7	11	11	12
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	7	8	9	3	11	27	15	25	23	29
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	1	0	2	0	1	1	1
20–24	2	5	0	1	3	5	7	6	2	8
25–29	3	2	3	1	4	17	15	10	12	9
30–34	4	7	2	2	2	8	16	16	13	11
35–39	10	7	2	4	7	23	10	16	14	12
40–44	3	10	5	3	6	11	13	7	3	18
45–49	5	6	4	3	3	12	8	15	8	3
50–54	2	6	6	4	6	12	8	4	8	11
55–59	2	3	3	4	4	8	8	8	6	3
60–64	4	5	3	2	3	6	5	7	7	5
≥ 65	3	6	3	6	4	4	7	3	3	6
Region of residence^a
Northeast	8	13	13	4	12	15	26	13	11	14
Midwest	6	2	1	3	3	19	5	11	10	11
South	11	22	11	13	18	30	27	29	21	32
West	13	18	7	9	7	45	38	38	35	28
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	38	55	32	29	40	108	96	92	77	85
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	3	3	4	3	5
15–19	23	32	26	18	18	137	131	95	75	97
20–24	123	108	112	85	95	401	391	375	281	333
25–29	197	226	170	151	167	516	473	440	364	413
30–34	197	229	184	157	201	534	461	458	390	451
35–39	219	207	180	142	185	469	452	425	317	428
40–44	185	165	164	139	162	405	424	374	278	366
45–49	187	170	193	120	138	393	360	328	268	323
50–54	199	196	169	110	135	345	325	319	215	268
55–59	187	161	158	126	144	294	300	272	197	254
60–64	124	100	131	88	124	196	172	191	137	154
≥ 65	112	107	119	89	102	165	130	155	88	118
Region of residence^a
Northeast	310	251	243	185	249	633	555	521	391	486
Midwest	191	202	187	135	141	499	478	475	362	409
South	1,186	1,164	1,108	852	1,012	2,485	2,317	2,187	1,666	2,085
West	65	79	68	52	68	237	271	250	193	228
U.S. dependent areas	0	5	0	2	0	3	1	3	2	1
Total	1,753	1,700	1,607	1,226	1,470	3,856	3,622	3,436	2,613	3,208
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	1	1	5	4	0	1
15–19	9	7	10	2	7	40	34	33	30	38
20–24	35	31	28	32	31	119	102	116	102	104
25–29	72	66	77	52	63	152	138	147	102	140
30–34	82	99	71	45	69	134	134	156	101	135
35–39	88	88	76	67	78	137	147	117	112	158
40–44	89	72	77	45	80	111	114	125	96	132
45–49	59	79	68	41	59	130	120	105	74	118
50–54	59	72	55	57	65	94	118	94	75	93
55–59	45	50	49	35	44	82	76	75	58	74
60–64	41	27	40	28	33	44	50	51	36	43
≥ 65	36	42	32	22	40	42	50	48	26	42
Region of residence^a
Northeast	140	139	106	83	133	262	246	228	195	223
Midwest	31	33	33	18	27	63	55	70	45	60
South	272	314	293	221	257	454	469	455	353	468
West	93	86	83	65	89	226	240	245	178	246
U.S. dependent areas	79	61	64	38	63	80	77	74	41	80
Total	615	633	580	426	569	1,085	1,088	1,071	812	1,077
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	0	1	1	1	0
20–24	1	0	0	0	0	0	0	1	1	1
25–29	1	0	1	0	0	2	0	1	2	0
30–34	1	1	0	1	0	3	2	1	1	1
35–39	0	0	0	1	0	2	0	2	1	1
40–44	1	0	0	0	0	0	0	1	1	2
45–49	1	0	0	0	0	0	0	0	1	0
50–54	0	0	0	0	0	0	1	1	1	2
55–59	0	0	0	0	1	0	0	0	2	0
60–64	0	0	0	0	0	0	0	0	1	0
≥ 65	1	0	0	0	0	0	0	0	0	0
Region of residence^a
Northeast	1	0	0	0	0	1	1	0	1	2
Midwest	0	0	0	0	0	0	0	4	0	0
South	1	1	0	0	1	2	0	1	4	1
West	2	0	1	2	1	4	3	2	8	4
U.S. dependent areas	1	0	0	0	0	0	0	1	0	0
Total	6	2	1	2	3	7	4	8	12	7
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	1	0	0	1
15–19	5	3	3	1	3	26	30	31	21	33
20–24	15	19	20	15	20	93	89	90	96	78
25–29	48	47	50	31	44	110	121	127	115	92
30–34	50	58	39	40	41	124	123	123	113	142
35–39	45	51	43	37	49	105	111	120	105	128
40–44	51	42	46	31	45	83	102	95	89	133
45–49	52	55	54	41	35	106	106	105	103	98
50–54	63	44	49	38	45	96	92	91	69	90
55–59	49	51	45	35	38	93	71	81	77	89
60–64	37	38	30	27	27	38	37	47	30	42
≥ 65	34	31	25	27	32	25	25	22	30	37
Region of residence^a
Northeast	82	79	62	65	63	115	104	107	98	95
Midwest	49	54	60	52	51	147	160	177	147	189
South	240	240	214	167	213	485	486	481	421	503
West	76	65	67	40	53	151	160	167	181	174
U.S. dependent areas	0	0	1	0	0	1	0	0	0	0
Total	447	438	405	324	379	899	909	932	847	962
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	0	0	0	0
15–19	1	1	1	1	1	9	13	12	10	3
20–24	5	5	4	4	2	29	26	27	23	18
25–29	12	11	8	1	5	24	44	38	29	27
30–34	14	14	11	5	7	31	38	25	20	26
35–39	13	6	7	4	7	32	30	23	16	27
40–44	14	5	10	5	8	15	17	22	11	17
45–49	10	8	8	6	6	25	28	22	12	13
50–54	6	10	8	5	6	16	14	19	10	14
55–59	8	4	8	3	4	15	9	7	9	11
60–64	9	3	3	2	3	4	12	8	10	6
≥ 65	6	4	8	1	3	7	8	7	3	7
Region of residence^a
Northeast	22	24	23	8	11	43	43	41	24	31
Midwest	12	9	14	5	12	31	34	33	30	21
South	56	34	34	20	26	106	127	108	86	96
West	8	3	5	3	2	27	33	29	13	21
U.S. dependent areas	0	1	0	0	0	1	0	0	0	0
Total	97	70	76	36	52	208	237	210	153	169
Total
Age at diagnosis (yr)
13–14	0	0	0	0	1	6	8	8	3	6
15–19	39	45	41	24	30	214	210	174	137	173
20–24	180	169	166	138	151	651	615	616	504	541
25–29	331	353	309	236	288	826	791	765	624	685
30–34	351	409	308	251	321	834	775	782	644	770
35–39	378	360	308	255	326	771	753	709	572	758
40–44	342	295	303	222	301	628	673	629	482	669
45–49	313	317	327	211	241	670	625	578	467	559
50–54	329	328	289	215	258	566	559	529	379	482
55–59	292	270	264	203	236	492	467	444	350	431
60–64	215	173	207	147	190	291	276	303	222	250
≥ 65	192	188	187	144	181	242	220	236	152	211
Region of residence^a
Northeast	564	506	448	344	469	1,068	974	910	721	851
Midwest	289	301	297	214	237	761	733	778	598	700
South	1,768	1,778	1,666	1,275	1,529	3,567	3,433	3,266	2,556	3,192
West	261	253	232	173	224	710	751	742	619	713
U.S. dependent areas	81	68	66	40	63	84	78	78	42	80
Total	2,962	2,906	2,709	2,046	2,523	6,190	5,970	5,773	4,536	5,536

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified heterosexual contact include transgender and additional gender identity persons. Includes persons who have ever had heterosexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs). Excludes men who have ever had sexual contact with both men and women.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 8a. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, assigned sex at birth, and selected characteristics, 2021—United States
	13–14 years		15–17 years		18–19 years		20–22 years		23–24 years		Total
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Sex at birth
Male	8	0.2	260	3.9	990	22.6	2,788	42.1	2,052	47.1	6,098	23.0
Female	7	0.2	63	1.0	139	3.3	349	5.5	271	6.5	829	3.3
Race/Ethnicity
American Indian/Alaska Native	0	0.0	2	1.8	10	14.1	14	12.8	7	9.8	33	7.6
Asian	0	0.0	2	0.3	21	4.6	43	6.0	51	10.1	117	4.2
Black/African American	8	0.7	194	11.0	631	54.1	1,720	94.6	1,144	95.0	3,697	51.5
Hispanic/Latino^b	6	0.3	81	2.5	287	13.8	783	25.8	697	36.1	1,854	14.7
Native Hawaiian/Other Pacific Islander	0	0.0	2	7.6	4	23.5	3	11.8	2	11.6	11	10.6
White	1	0.0	28	0.4	128	2.9	468	6.8	346	7.6	971	3.6
Multiracial	0	0.0	14	2.7	48	15.6	106	24.1	76	28.0	244	12.8
Transmission category^c
Male sex at birth^d
Male-to-male sexual contact^e	5	—	246	—	947	—	2,599	—	1,874	—	5,671	—
Injection drug use^f	0	—	1	—	5	—	36	—	41	—	84	—
Male-to-male sexual contact^e and injection drug use^f	1	—	3	—	16	—	67	—	70	—	156	—
Heterosexual contact^g	1	—	6	—	21	—	84	—	66	—	178	—
Perinatal^h	1	—	3	—	1	—	2	—	1	—	8	—
Otherⁱ	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	8	0.2	260	3.9	990	22.6	2,788	42.1	2,052	47.1	6,098	23.0
Female sex at birth^d
Injection drug use^f	1	—	4	—	13	—	36	—	37	—	91	—
Heterosexual contact^g	6	—	51	—	121	—	304	—	229	—	710	—
Perinatal^h	0	—	8	—	5	—	10	—	5	—	28	—
Otherⁱ	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	7	0.2	63	1.0	139	3.3	349	5.5	271	6.5	829	3.3
Region of residence^j
Northeast	2	0.1	54	2.6	120	8.1	378	17.3	322	23.0	876	10.2
Midwest	5	0.3	45	1.6	156	8.7	475	17.1	304	17.1	985	9.0
South	5	0.1	163	3.2	675	20.6	1,793	36.0	1,275	38.9	3,911	19.5
West	3	0.1	61	2.0	178	8.9	491	16.2	422	20.2	1,155	9.3
Total	15	0.2	323	2.5	1,129	13.2	3,137	24.2	2,323	27.2	6,927	13.3

Note: Numbers less than 12 should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.
^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^c Data include transgender and additional gender identity persons.
^d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱ Data are based on residence at time of diagnosis of HIV infection.

Table 8b. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, assigned sex at birth, and selected characteristics, 2021—United States and 6 dependent areas
	13–14 years	15–17 years	18–19 years	20–22 years	23–24 years	Total
	No.	No.	No.	No.	No.	No.
Sex at birth
Male	8	260	996	2,814	2,069	6,147
Female	7	64	140	353	276	840
Race/Ethnicity
American Indian/Alaska Native	0	2	10	14	7	33
Asian	0	2	21	43	51	117
Black/African American	8	194	631	1,721	1,144	3,698
Hispanic/Latino^a	6	82	294	812	719	1,913
Native Hawaiian/Other Pacific Islander	0	2	4	3	2	11
White	1	28	128	468	346	971
Multiracial	0	14	48	106	76	244
Transmission category^b
Male sex at birth^c
Male-to-male sexual contact^d	5	246	949	2,625	1,890	5,715
Injection drug use^e	0	1	5	36	41	84
Male-to-male sexual contact^d and injection drug use^e	1	3	17	67	70	157
Heterosexual contact^f	1	6	24	84	67	182
Perinatal^g	1	3	1	2	1	8
Other^h	0	0	0	0	0	0
Subtotal	8	260	996	2,814	2,069	6,147
Female sex at birth^c
Injection drug use^e	1	4	13	36	37	91
Heterosexual contact^f	6	52	122	308	234	721
Perinatal^g	0	8	5	10	5	28
Other^h	0	0	0	0	0	0
Subtotal	7	64	140	353	276	840
Region of residenceⁱ
Northeast	2	54	120	378	322	876
Midwest	5	45	156	475	304	985
South	5	163	675	1,793	1,275	3,911
West	3	61	178	491	422	1,155
U.S. dependent areas	0	1	7	30	22	60
Total	15	324	1,136	3,167	2,345	6,987

Note: Numbers less than 12 should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.
^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^c Data include transgender and additional gender identity persons.
^d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱ Data are based on residence at time of diagnosis of HIV infection.

Table 9a. Diagnoses of HIV infection among children aged < 13 years, by year of diagnosis and race/ethnicity, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
American Indian/Alaska Native	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0
Asian	8	0.3	6	0.2	6	0.2	2	0.1	2	0.1
Black/African American	56	0.8	49	0.7	31	0.4	35	0.5	33	0.5
Hispanic/Latino^b	15	0.1	10	0.1	7	0.1	9	0.1	11	0.1
Native Hawaiian/other Pacific Islander	1	0.9	0	0.0	0	0.0	1	0.9	0	0.0
White	15	0.1	15	0.1	7	0.0	12	0.0	5	0.0
Multiracial	10	0.4	6	0.2	5	0.2	0	0.0	2	0.1
Total	105	0.2	86	0.2	57	0.1	60	0.1	53	0.1

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.
^b Hispanic/Latino persons can be of any race.

Table 9b. Diagnoses of HIV infection among children aged < 13 years, by year of diagnosis and race/ethnicity, 2017–2021—United States and 6 dependent areas
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	0	1	1	0
Asian	8	6	6	2	2
Black/African American	56	49	31	35	33
Hispanic/Latino^a	15	10	7	9	11
Native Hawaiian/other Pacific Islander	1	0	0	1	0
White	15	15	7	12	5
Multiracial	10	6	5	0	2
Total	105	86	57	60	53

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.

Table 10a. Diagnoses of HIV infection among Hispanic/Latino persons aged ≥ 13 years, by place of birth and transmission category, 2021—United States and 6 dependent areas
									Caribbean^a
	United States		South America^b		Central America^c		Mexico		Puerto Rico		Cuba		Other		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.^d	%
Transmission category^e
Male sex at birth^f
Male-to-male sexual contact^g	2,472	85.4	646	92.2	442	90.1	827	86.8	325	77.7	302	90.6	117.0	72.9	8,000	86.8
Injection drug use^h	105	3.6	8	1.1	8	1.6	24	2.5	26	6.1	2	0.5	5.0	3.3	318	3.4
Male-to-male sexual contact^g and injection drug use^h	159	5.5	7	1	6	1.1	25	2.6	7	1.6	2	0.5	3.0	2.0	327	3.5
Heterosexual contactⁱ	157	5.4	39	5.6	33	6.7	77	8.0	61	14.5	28	8.4	35.0	21.7	569	6.2
Perinatal^j	0	0.0	1	0.2	2	0.4	0	0.0	0	0.0	0	0.0	0.0	0.0	3	0.0
Other^k	1	0.0	0	0.0	0	0	1	0.1	0	0.0	0	0.0	0.0	0.1	4	0.0
Subtotal	2,894	100	701	100	491	100	953	100	418	100	333	100	161	100	9,222	100
Female sex at birth^f
Injection drug use^h	71	18.3	3	4	5	4.3	6	9.1	6	6.0	1	1.1	5.0	6.8	162	13.0
Heterosexual contactⁱ	315	81.5	69	94.7	99	92.9	62	90.3	93	94.0	46	98.5	64.0	93.0	1,077	86.5
Perinatal^j	1	0.2	1	1.4	3	2.7	0	0.6	0	0.0	0	0.4	0.0	0.1	6	0.5
Other^k	0	0.0	0	0	0	0.1	0	0.0	0	0.0	0	0.0	0.0	0.0	0	0.0
Subtotal	387	100	73	100	107	100	69	100	99	100	47	100	69	100	1,245	100
Total	3,281	100	774	100	598	100	1,022	100	517	100	380	100	230	100	10,467	100

Note. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

^a Countries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S.).
^b Countries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
^c Countries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
^d Total includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Data include transgender and additional gender identity persons.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

TTable 10b. Diagnoses of HIV infection among transgender and additional gender identity Hispanic/Latino persons ≥ 13 years, by place of birth and exposure category, 2021—United States and 6 dependent areas
									Caribbean^a
	United States		South America^b		Central America^c		Mexico		Puerto Rico		Cuba		Other		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.^d	%
Exposure category^e
Transgender woman^f
Sexual contact^g	74	88.1	8	100	23	100	33	97.1	6	85.7	7	100	5	100	237	91.9
Injection drug use^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4
Sexual contact^g and injection drug use^h	8	9.5	0	0.0	0	0.0	0	0.0	1	14.3	0	0.0	0	0.0	13	5.0
Otherⁱ	2	2.4	0	0.0	0	0.0	1	2.9	0	0.0	0	0.0	0	0.0	7	2.7
Subtotal	84	100	8	100	23	100	34	100	7	100	7	100	5	100	258	100
Transgender man^f
Sexual contact^g	9	90.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	12	85.7
Injection drug use^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sexual contact^g and injection drug use^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Otherⁱ	1	10.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	14.3
Subtotal	10	100	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	14	100
Additional gender identity^j
Sexual contact^g	7	77.8	0	0.0	1	100	0	0.0	0	0.0	0	0.0	1	100	11	78.6
Injection drug use^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sexual contact^g and injection drug use^h	1	11.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	14.3
Otherⁱ	1	11.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	7.1
Subtotal	9	100	0	0.0	1	100	0	0.0	0	0.0	0	0.0	1	100	14	100
Total	103	100	8	100	24	100	34	100	7	100	7	100	6	100	286	100

Note. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

^a Countries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S.).
^b Countries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
^c Countries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
^d Total includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
^e Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^f “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^g For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 11a. Deaths (any cause) of persons with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	12,240	—	12,102	—	12,309	—	14,210	—	14,663	—
Female	3,989	—	3,986	—	3,841	—	4,630	—	4,743	—
Transgender woman/girl^b	108	—	118	—	145	—	207	—	215	—
Transgender man/boy^b	5	—	5	—	5	—	10	—	2	—
Additional gender identity^c	3	—	1	—	2	—	0	—	1	—
Age at death (yr)
< 13	2	0.0	1	0.0	2	0.0	5	0.0	1	0.0
13–14	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0
15–19	7	0.0	9	0.0	11	0.1	13	0.1	4	0.0
20–24	145	0.7	121	0.6	123	0.6	140	0.7	105	0.5
25–29	445	1.9	420	1.8	436	1.9	461	2.0	459	2.0
30–34	602	2.7	614	2.8	664	3.0	797	3.5	901	3.9
35–39	863	4.1	814	3.8	858	3.9	940	4.2	1,070	4.8
40–44	970	5.0	960	4.9	937	4.7	1,134	5.5	1,177	5.6
45–49	1,742	8.3	1,603	7.7	1,402	6.9	1,511	7.4	1,522	7.7
50–54	2,727	12.8	2,580	12.4	2,246	11.0	2,347	11.3	2,261	10.8
55–59	2,967	13.5	2,930	13.4	2,921	13.4	3,299	15.0	3,370	15.6
60–64	2,487	12.5	2,525	12.4	2,669	13.0	3,177	15.1	3,269	15.4
≥ 65	3,388	6.7	3,635	6.9	4,032	7.5	5,233	9.6	5,485	9.8
Race/ethnicity
American Indian/Alaska Native	47	2.0	49	2.0	57	2.4	82	3.4	80	3.3
Asian^d	88	0.5	83	0.4	100	0.5	103	0.5	125	0.6
Black/African American	7,194	17.7	6,982	17.1	7,009	17.0	8,330	20.0	8,402	20.1
Hispanic/Latino^e	2,693	4.6	2,838	4.8	2,771	4.6	3,452	5.6	3,499	5.6
Native Hawaiian/other Pacific Islander	9	1.5	13	2.2	14	2.3	11	1.8	14	2.2
White	5,235	2.6	5,150	2.6	5,256	2.7	5,756	2.9	6,025	3.1
Multiracial	1,077	15.4	1,097	15.3	1,091	14.8	1,322	17.3	1,478	19.0
Transmission category^f
Male sex at birth (≥ 13 yrs at death)^g
Male-to-male sexual contact^h	7,010	—	6,888	—	7,184	—	8,237	—	8,672	—
Injection drug useⁱ	2,154	—	2,169	—	2,087	—	2,427	—	2,335	—
Male-to-male sexual contact^h and injection drug useⁱ	1,383	—	1,453	—	1,395	—	1,665	—	1,687	—
Heterosexual contact^j	1,694	—	1,600	—	1,688	—	1,961	—	2,071	—
Perinatal^k	41	—	51	—	41	—	57	—	54	—
Other^l	67	—	58	—	59	—	67	—	60	—
Subtotal	12,350	9.3	12,220	9.1	12,454	9.2	14,415	10.5	14,879	10.8
Female sex at birth (≥ 13 yrs at death)^g
Injection drug useⁱ	1,373	—	1,335	—	1,316	—	1,494	—	1,466	—
Heterosexual contact^j	2,548	—	2,594	—	2,470	—	3,060	—	3,191	—
Perinatal^k	43	—	37	—	37	—	45	—	52	—
Other^l	29	—	26	—	24	—	38	—	36	—
Subtotal	3,993	2.9	3,991	2.8	3,846	2.7	4,637	3.3	4,744	3.3
Child (< 13 yrs at death)
Perinatal	2	—	1	—	1	—	4	—	1	—
Other^l	0	—	0	—	1	—	1	—	0	—
Subtotal	2	0.0	1	0.0	2	0.0	5	0.0	1	0.0
Region of residence^m
Northeast	3,693	6.6	3,523	6.3	3,653	6.5	4,524	7.9	4,324	7.6
Midwest	1,915	2.8	2,003	2.9	1,961	2.9	2,316	3.4	2,284	3.3
South	7,997	6.5	7,880	6.3	7,917	6.3	9,078	7.2	9,540	7.5
West	2,740	3.5	2,806	3.6	2,771	3.5	3,139	4.0	3,476	4.4
Totalⁿ	16,345	5.0	16,212	5.0	16,302	5.0	19,057	5.7	19,624	5.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Data include transgender and additional gender identity persons.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^m Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
ⁿ Includes persons whose race/ethnicity is unknown.

Table 11b. Deaths (any cause) of persons with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	12,541	—	12,392	—	12,585	—	14,484	—	14,942	—
Female	4,097	—	4,062	—	3,920	—	4,716	—	4,825	—
Transgender woman/girl^b	110	—	119	—	147	—	208	—	216	—
Transgender man/boy^b	5	—	5	—	5	—	10	—	2	—
Additional gender identity^c	3	—	1	—	2	—	0	—	1	—
Age at death (yr)
< 13	2	0.0	1	0.0	2	0.0	5	0.0	1	0.0
13–14	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0
15–19	7	0.0	9	0.0	11	0.1	13	0.1	4	0.0
20–24	147	0.7	125	0.6	125	0.6	142	0.7	106	0.5
25–29	451	1.9	428	1.8	442	1.9	463	2.0	467	2.1
30–34	617	2.8	626	2.8	676	3.0	803	3.5	906	3.9
35–39	878	4.1	833	3.8	875	4.0	963	4.3	1,084	4.8
40–44	1,005	5.1	989	5.0	976	4.8	1,165	5.6	1,206	5.7
45–49	1,794	8.5	1,641	7.8	1,438	7.0	1,546	7.5	1,552	7.8
50–54	2,804	13.0	2,631	12.5	2,319	11.2	2,393	11.4	2,302	10.9
55–59	3,049	13.7	3,000	13.5	2,973	13.4	3,374	15.1	3,429	15.7
60–64	2,529	12.5	2,574	12.5	2,722	13.1	3,227	15.2	3,325	15.5
≥ 65	3,473	6.7	3,722	7.0	4,099	7.5	5,324	9.6	5,604	9.9
Race/ethnicity
American Indian/Alaska Native	47	—	49	—	57	—	82	—	80	—
Asian^d	88	—	83	—	100	—	104	—	125	—
Black/African American	7,199	—	6,982	—	7,010	—	8,333	—	8,405	—
Hispanic/Latino^e	3,098	—	3,200	—	3,120	—	3,807	—	3,858	—
Native Hawaiian/other Pacific Islander	9	—	16	—	16	—	11	—	14	—
White	5,236	—	5,151	—	5,258	—	5,758	—	6,025	—
Multiracial	1,077	—	1,098	—	1,094	—	1,322	—	1,478	—
Transmission category^f
Male sex at birth (≥ 13 yrs at death)^g
Male-to-male sexual contact^h	7,081	—	6,967	—	7,257	—	8,319	—	8,730	—
Injection drug useⁱ	2,286	—	2,290	—	2,209	—	2,534	—	2,451	—
Male-to-male sexual contact^h and injection drug useⁱ	1,408	—	1,475	—	1,420	—	1,695	—	1,714	—
Heterosexual contact^j	1,768	—	1,663	—	1,744	—	2,015	—	2,149	—
Perinatal^k	42	—	57	—	43	—	60	—	55	—
Other^l	67	—	59	—	59	—	67	—	60	—
Subtotal	12,653	9.4	12,511	9.2	12,732	9.3	14,690	10.6	15,159	10.9
Female sex at birth (≥ 13 yrs at death)^g
Injection drug useⁱ	1,409	—	1,368	—	1,345	—	1,521	—	1,486	—
Heterosexual contact^j	2,620	—	2,635	—	2,517	—	3,119	—	3,253	—
Perinatal^k	44	—	39	—	38	—	45	—	52	—
Other^l	29	—	26	—	25	—	38	—	36	—
Subtotal	4,101	2.9	4,067	2.9	3,925	2.8	4,723	3.3	4,826	3.4
Child (< 13 yrs at death)
Perinatal	2	—	1	—	1	—	4	—	1	—
Other^l	0	—	0	—	1	—	1	—	0	—
Subtotal	2	0.0	1	0.0	2	0.0	5	0.0	1	0.0
Region of residence^m
Northeast	3,693	6.6	3,523	6.3	3,653	6.5	4,524	7.9	4,324	7.6
Midwest	1,915	2.8	2,003	2.9	1,961	2.9	2,316	3.4	2,284	3.3
South	7,997	6.5	7,880	6.3	7,917	6.3	9,078	7.2	9,540	7.5
West	2,740	3.5	2,806	3.6	2,771	3.5	3,139	4.0	3,476	4.4
U.S. dependent areas	411	11.0	367	10.2	357	9.9	361	9.8	362	9.9
Totalⁿ	16,756	5.1	16,579	5.0	16,659	5.0	19,418	5.8	19,986	6.0

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.

^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Data include transgender and additional gender identity persons.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^m Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
ⁿ Includes persons whose race/ethnicity is unknown.

Table 12a. Deaths (any cause) of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2021—United States
	American Indian/Alaska Native		Asian^a		Black/African American		Hispanic/Latino^b		Native Hawaiian/other Pacific Islander		White		Multiracial		Total^c
	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d
Gender
Male	53	—	100	—	5,599	—	2,720	—	14	—	5,076	—	1,101	—	14,663	—
Female	22	—	23	—	2,703	—	720	—	0	—	923	—	351	—	4,743	—
Transgender woman/girl^e	5	—	2	—	99	—	58	—	0	—	26	—	25	—	215	—
Transgender man/boy^e	0	—	0	—	1	—	1	—	0	—	0	—	0	—	2	—
Additional gender identity^f	0	—	0	—	0	—	0	—	0	—	0	—	1	—	1	—
Age at death (yr)
< 13	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	3	0.1	1	0.0	0	0.0	0	0.0	0	0.0	4	0.0
20–24	0	0.0	0	0.0	50	1.7	29	0.6	0	0.0	18	0.2	8	1.1	105	0.5
25–29	2	1.1	4	0.3	239	7.3	95	2.0	0	0.0	85	0.7	34	5.5	459	2.0
30–34	10	5.3	8	0.5	423	12.9	202	4.3	0	0.0	193	1.5	65	13.1	901	3.9
35–39	8	4.9	9	0.5	491	17.1	233	5.1	1	1.9	259	2.1	69	17.3	1,070	4.8
40–44	12	8.0	8	0.5	499	18.4	255	5.8	2	4.4	307	2.6	94	27.4	1,177	5.6
45–49	11	7.9	16	1.1	647	25.9	304	7.7	1	2.6	436	3.8	107	38.1	1,522	7.7
50–54	4	2.8	19	1.5	931	36.2	442	12.4	4	10.9	680	5.2	181	70.4	2,261	10.8
55–59	9	5.9	19	1.6	1,351	51.6	591	19.2	3	8.4	1,114	7.8	283	119.9	3,370	15.6
60–64	10	6.8	14	1.3	1,412	57.7	511	20.8	2	6.3	1,078	7.2	242	110.9	3,269	15.4
≥ 65	14	4.3	28	1.0	2,356	44.6	835	16.5	1	1.5	1,855	4.4	395	83.1	5,485	9.8
Transmission category^g
Male sex at birth (≥ 13 yrs at death)^h
Male-to-male sexual contactⁱ	34	—	82	—	2,746	—	1,561	—	12	—	3,603	—	634	—	8,672	—
Injection drug use^j	8	—	4	—	1,085	—	544	—	0	—	521	—	173	—	2,335	—
Male-to-male sexual contactⁱ and injection drug use^j	11	—	3	—	483	—	354	—	1	—	653	—	184	—	1,687	—
Heterosexual contact^k	5	—	12	—	1,344	—	291	—	1	—	295	—	123	—	2,071	—
Perinatal^l	0	—	0	—	28	—	15	—	0	—	5	—	5	—	54	—
Other^m	0	—	1	—	13	—	13	—	0	—	25	—	8	—	60	—
Subtotal	58	5.8	102	1.3	5,698	34.5	2,778	11.2	14	5.4	5,102	6.0	1,127	44.1	14,879	10.8
Female sex at birth (≥ 13 yrs at death)^h
Injection drug use^j	10	—	5	—	687	—	256	—	0	—	383	—	125	—	1,466	—
Heterosexual contact^k	13	—	18	—	1,976	—	447	—	0	—	521	—	217	—	3,191	—
Perinatal^l	0	—	0	—	31	—	12	—	0	—	6	—	2	—	52	—
Other^m	0	—	0	—	10	—	6	—	0	—	12	—	7	—	36	—
Subtotal	22	2.1	23	0.3	2,704	14.8	720	3.0	0	0.0	923	1.1	351	13.1	4,744	3.3
Child (< 13 yrs at death)
Perinatal	0	—	0	—	0	—	1	—	0	—	0	—	0	—	1	—
Other^m	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Region of residenceⁿ
Northeast	1	0.8	23	0.6	1,653	25.4	1,225	14.0	0	0.0	993	2.7	429	40.5	4,324	7.6
Midwest	6	1.4	12	0.5	944	12.9	188	3.2	2	4.9	930	1.8	202	13.5	2,284	3.3
South	9	1.1	28	0.6	5,208	21.3	1,155	4.8	1	1.0	2,554	3.6	585	22.4	9,540	7.5
West	64	6.0	62	0.7	597	16.4	931	3.9	11	2.4	1,548	4.0	262	10.0	3,476	4.4
Total	80	3.3	125	0.6	8,402	20.1	3,499	5.6	14	2.2	6,025	3.1	1,478	19.0	19,624	5.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for the year 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^b Hispanic/Latino persons can be of any race.
^c Includes persons whose race/ethnicity is unknown.
^d Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^e “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^h Data include transgender and additional gender identity persons.
ⁱ Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^j Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^k Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^l Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^m Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁿ Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 12b. Deaths (any cause) of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2021—United States and 6 dependent areas
	American Indian/Alaska Native	Asian^a	Black/African American	Hispanic/Latino^b	Native Hawaiian/other Pacific Islander	White	Multiracial	Total^c
	No.	No.	No.	No.	No.	No.	No.	No.
Gender
Male	53	100	5,601	2,997	14	5,076	1,101	14,942
Female	22	23	2,704	801	0	923	351	4,825
Transgender woman/girl^d	5	2	99	59	0	26	25	216
Transgender man/boy^d	0	0	1	1	0	0	0	2
Additional gender identity^e	0	0	0	0	0	0	1	1
Age at death (yr)
< 13	0	0	0	1	0	0	0	1
13–14	0	0	0	0	0	0	0	0
15–19	0	0	3	1	0	0	0	4
20–24	0	0	50	30	0	18	8	106
25–29	2	4	240	102	0	85	34	467
30–34	10	8	423	207	0	193	65	906
35–39	8	9	491	247	1	259	69	1,084
40–44	12	8	499	284	2	307	94	1,206
45–49	11	16	647	334	1	436	107	1,552
50–54	4	19	931	483	4	680	181	2,302
55–59	9	19	1,351	650	3	1,114	283	3,429
60–64	10	14	1,412	567	2	1,078	242	3,325
≥ 65	14	28	2,358	952	1	1,855	395	5,604
Transmission category^f
Male sex at birth (≥ 13 yrs at death)^g
Male-to-male sexual contact^h	34	82	2,748	1,617	12	3,603	634	8,730
Injection drug useⁱ	8	4	1,085	660	0	521	173	2,451
Male-to-male sexual contact^h and injection drug useⁱ	11	3	483	380	1	653	184	1,714
Heterosexual contact^j	5	12	1,344	370	1	295	123	2,149
Perinatal^k	0	0	28	16	0	5	5	55
Other^l	0	1	13	13	0	25	8	60
Subtotal	58	102	5,700	3,056	14	5,102	1,127	15,159
Female sex at birth (≥ 13 yrs at death)^g
Injection drug useⁱ	10	5	687	276	0	383	125	1,486
Heterosexual contact^j	13	18	1,977	507	0	521	217	3,253
Perinatal^k	0	0	31	12	0	6	2	52
Other^l	0	0	10	6	0	12	7	36
Subtotal	22	23	2,705	801	0	923	351	4,826
Child (< 13 yrs at death)
Perinatal	0	0	0	1	0	0	0	1
Other^l	0	0	0	0	0	0	0	0
Subtotal	0	0	0	1	0	0	0	1
Region of residence^m
Northeast	1	23	1,653	1,225	0	993	429	4,324
Midwest	6	12	944	188	2	930	202	2,284
South	9	28	5,208	1,155	1	2,554	585	9,540
West	64	62	597	931	11	1,548	262	3,476
U.S. dependent areas	0	0	3	359	0	0	0	362
Total	80	125	8,405	3,858	14	6,025	1,478	19,986

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for the year 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^b Hispanic/Latino persons can be of any race.
^c Includes persons whose race/ethnicity is unknown.
^d “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^e Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Data include transgender and additional gender identity persons.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^m Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 13a. Deaths (any cause) of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, assigned sex at birth, and selected characteristics, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at death (yr)
13–14	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0
15–19	5	0.0	5	0.0	9	0.1	9	0.1	4	0.0
20–24	113	1.0	95	0.9	95	0.9	110	1.0	81	0.7
25–29	347	2.9	346	2.9	370	3.1	361	3.1	366	3.2
30–34	447	4.0	464	4.1	510	4.5	603	5.2	746	6.4
35–39	624	5.9	577	5.4	618	5.7	696	6.2	837	7.4
40–44	659	6.8	633	6.5	643	6.5	806	7.8	842	7.9
45–49	1,226	11.8	1,130	11.0	983	9.7	1,046	10.3	1,067	10.8
50–54	2,035	19.4	1,901	18.5	1,668	16.5	1,749	16.9	1,628	15.6
55–59	2,246	21.0	2,255	21.2	2,277	21.4	2,544	23.4	2,526	23.8
60–64	1,934	20.3	1,908	19.6	2,062	20.9	2,445	23.9	2,479	24.0
≥ 65	2,714	12.1	2,906	12.5	3,218	13.4	4,046	16.5	4,303	17.1
Race/ethnicity
American Indian/Alaska Native	33	3.4	33	3.4	38	3.9	49	4.9	58	5.8
Asian^c	73	1.0	72	1.0	92	1.2	88	1.1	102	1.3
Black/African American	4,910	31.2	4,707	29.6	4,800	29.9	5,714	34.9	5,698	34.5
Hispanic/Latino^d	2,109	9.3	2,254	9.7	2,201	9.3	2,715	11.1	2,778	11.2
Native Hawaiian/other Pacific Islander	5	2.1	12	5.0	9	3.6	10	3.9	14	5.4
White	4,409	5.2	4,319	5.1	4,486	5.3	4,895	5.8	5,102	6.0
Multiracial	810	36.8	823	36.1	825	34.9	943	38.2	1,127	44.1
Transmission category^e
Male-to-male sexual contact^f	7,010	—	6,888	—	7,184	—	8,237	—	8,672	—
Injection drug use^g	2,154	—	2,169	—	2,087	—	2,427	—	2,335	—
Male-to-male sexual contact^f and injection drug use^g	1,383	—	1,453	—	1,395	—	1,665	—	1,687	—
Heterosexual contact^h	1,694	—	1,600	—	1,688	—	1,961	—	2,071	—
Perinatalⁱ	41	—	51	—	41	—	57	—	54	—
Other^j	67	—	58	—	59	—	67	—	60	—
Region of residence^k
Northeast	2,620	11.3	2,486	10.7	2,604	11.3	3,224	13.5	3,103	13.0
Midwest	1,513	5.4	1,597	5.7	1,574	5.6	1,866	6.5	1,819	6.3
South	5,822	11.6	5,713	11.3	5,880	11.5	6,600	12.7	6,936	13.3
West	2,395	7.5	2,424	7.5	2,396	7.4	2,725	8.3	3,021	9.1
Subtotal	12,350	9.3	12,220	9.1	12,454	9.2	14,415	10.5	14,879	10.8
Female sex at birth^b
Age at death (yr)
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	2	0.0	4	0.0	2	0.0	4	0.0	0	0.0
20–24	32	0.3	26	0.2	28	0.3	30	0.3	24	0.2
25–29	98	0.9	74	0.6	66	0.6	100	0.9	93	0.8
30–34	155	1.4	150	1.4	154	1.4	194	1.7	155	1.4
35–39	239	2.3	237	2.2	240	2.2	244	2.2	233	2.1
40–44	311	3.2	327	3.3	294	2.9	328	3.2	335	3.2
45–49	516	4.9	473	4.5	419	4.1	465	4.6	455	4.6
50–54	692	6.4	679	6.4	578	5.6	598	5.7	633	6.0
55–59	721	6.4	675	6.0	644	5.7	755	6.8	844	7.7
60–64	553	5.3	617	5.8	607	5.7	732	6.8	790	7.2
≥ 65	674	2.4	729	2.5	814	2.7	1,187	4.0	1,182	3.9
Race/ethnicity
American Indian/Alaska Native	14	1.4	16	1.6	19	1.9	33	3.2	22	2.1
Asian^c	15	0.2	11	0.1	8	0.1	15	0.2	23	0.3
Black/African American	2,283	13.0	2,274	12.8	2,208	12.3	2,613	14.4	2,704	14.8
Hispanic/Latino^d	584	2.6	584	2.6	569	2.4	737	3.1	720	3.0
Native Hawaiian/other Pacific Islander	4	1.7	1	0.4	5	2.0	1	0.4	0	0.0
White	825	0.9	831	1.0	770	0.9	859	1.0	923	1.1
Multiracial	267	11.4	274	11.3	266	10.6	379	14.6	351	13.1
Transmission category^e
Injection drug use^g	1,373	—	1,335	—	1,316	—	1,494	—	1,466	—
Heterosexual contact^h	2,548	—	2,593	—	2,470	—	3,060	—	3,191	—
Perinatalⁱ	43	—	37	—	37	—	45	—	52	—
Other^j	29	—	26	—	24	—	38	—	36	—
Region of residence^k
Northeast	1,073	4.3	1,036	4.2	1,049	4.2	1,298	5.2	1,221	4.9
Midwest	401	1.4	406	1.4	386	1.3	450	1.5	465	1.6
South	2,174	4.1	2,167	4.0	2,036	3.8	2,476	4.6	2,603	4.8
West	345	1.1	382	1.2	375	1.1	413	1.3	455	1.4
Subtotal	3,993	2.9	3,991	2.8	3,846	2.7	4,637	3.3	4,744	3.3
Total	16,343	6.0	16,211	5.9	16,300	5.9	19,052	6.8	19,623	7.0

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
^b Data include transgender and additional gender identity persons.
^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 13b. Deaths (any cause) of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, assigned sex at birth, and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at death (yr)
13–14	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0
15–19	5	0.0	5	0.0	9	0.1	9	0.1	4	0.0
20–24	114	1.0	99	0.9	97	0.9	112	1.0	82	0.7
25–29	351	2.9	353	2.9	374	3.1	363	3.1	373	3.2
30–34	457	4.1	472	4.2	516	4.5	607	5.2	750	6.4
35–39	635	5.9	590	5.4	629	5.7	715	6.3	847	7.5
40–44	687	7.0	656	6.6	671	6.7	831	7.9	867	8.1
45–49	1,267	12.1	1,157	11.2	1,010	9.9	1,067	10.4	1,091	10.9
50–54	2,094	19.7	1,939	18.7	1,728	16.9	1,784	17.0	1,664	15.8
55–59	2,304	21.4	2,310	21.4	2,317	21.5	2,602	23.7	2,569	23.9
60–64	1,963	20.4	1,950	19.9	2,104	21.1	2,481	24.0	2,522	24.1
≥ 65	2,776	12.2	2,980	12.6	3,276	13.4	4,119	16.6	4,390	17.2
Race/ethnicity
American Indian/Alaska Native	33	—	33	—	38	—	49	—	58	—
Asian^c	73	—	72	—	92	—	89	—	102	—
Black/African American	4,914	—	4,707	—	4,801	—	5,715	—	5,700	—
Hispanic/Latino^d	2,407	—	2,542	—	2,472	—	2,986	—	3,056	—
Native Hawaiian/other Pacific Islander	5	—	13	—	11	—	10	—	14	—
White	4,410	—	4,320	—	4,488	—	4,897	—	5,102	—
Multiracial	810	—	824	—	827	—	943	—	1,127	—
Transmission category^e
Male-to-male sexual contact^f	7,082	—	6,967	—	7,257	—	8,320	—	8,730	—
Injection drug use^g	2,286	—	2,290	—	2,209	—	2,534	—	2,451	—
Male-to-male sexual contact^f and injection drug use^g	1,408	—	1,475	—	1,420	—	1,695	—	1,714	—
Heterosexual contact^h	1,768	—	1,663	—	1,744	—	2,015	—	2,149	—
Perinatalⁱ	42	—	57	—	43	—	60	—	55	—
Other^j	67	—	59	—	59	—	67	—	60	—
Region of residence^k
Northeast	2,620	11.3	2,486	10.7	2,604	11.3	3,224	13.5	3,103	13.0
Midwest	1,513	5.4	1,597	5.7	1,574	5.6	1,866	6.5	1,819	6.3
South	5,822	11.6	5,713	11.3	5,880	11.5	6,600	12.7	6,936	13.3
West	2,395	7.5	2,424	7.5	2,396	7.4	2,725	8.3	3,021	9.1
US dependent areas	303	20.0	291	19.8	278	18.8	275	18.1	280	18.4
Subtotal	12,653	9.4	12,511	9.2	12,732	9.3	14,690	10.6	15,159	10.9
Female sex at birth^b
Age at death (yr)
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	2	0.0	4	0.0	2	0.0	4	0.0	0	0.0
20–24	33	0.3	26	0.2	28	0.3	30	0.3	24	0.2
25–29	100	0.9	75	0.6	68	0.6	100	0.9	94	0.8
30–34	160	1.5	154	1.4	160	1.4	196	1.7	156	1.4
35–39	243	2.3	243	2.2	246	2.2	248	2.2	237	2.1
40–44	318	3.2	333	3.3	305	3.0	334	3.2	339	3.2
45–49	527	4.9	484	4.6	428	4.1	479	4.7	461	4.6
50–54	710	6.5	692	6.5	591	5.6	609	5.8	638	6.0
55–59	745	6.5	690	6.1	656	5.8	772	6.8	860	7.8
60–64	566	5.4	624	5.8	618	5.7	746	6.8	803	7.3
≥ 65	697	2.4	742	2.5	823	2.7	1,205	4.0	1,214	3.9
Race/ethnicity
American Indian/Alaska Native	14	—	16	—	19	—	33	—	22	—
Asian^c	15	—	11	—	8	—	15	—	23	—
Black/African American	2,284	—	2,274	—	2,208	—	2,615	—	2,705	—
Hispanic/Latino^d	691	—	658	—	647	—	821	—	801	—
Native Hawaiian/other Pacific Islander	4	—	3	—	5	—	1	—	0	—
White	825	—	831	—	770	—	859	—	923	—
Multiracial	267	—	274	—	267	—	379	—	351	—
Transmission category^e
Injection drug use^g	1,408	—	1,368	—	1,346	—	1,521	—	1,486	—
Heterosexual contact^h	2,620	—	2,634	—	2,517	—	3,119	—	3,253	—
Perinatalⁱ	44	—	39	—	38	—	45	—	52	—
Other^j	29	—	26	—	25	—	38	—	36	—
Region of residence^k
Northeast	1,073	4.3	1,036	4.2	1,049	4.2	1,298	5.2	1,221	4.9
Midwest	401	1.4	406	1.4	386	1.3	450	1.5	465	1.6
South	2,174	4.1	2,167	4.0	2,036	3.8	2,476	4.6	2,603	4.8
West	345	1.1	382	1.2	375	1.1	413	1.3	455	1.4
US dependent areas	108	6.4	76	4.6	79	4.8	86	5.1	82	4.8
Subtotal	4,101	2.9	4,067	2.9	3,925	2.8	4,723	3.3	4,826	3.4
Total	16,754	6.1	16,578	6.0	16,657	6.0	19,413	6.9	19,985	7.1

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
^b Data include transgender and additional gender identity persons.
^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 14a. Deaths (any cause) of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
Transgender woman^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	2	1	5	7	5
25–29	8	12	17	17	12
30–34	9	9	19	30	41
35–39	15	13	17	29	29
40–44	12	12	17	23	27
45–49	19	12	17	26	15
50–54	11	19	17	21	20
55–59	19	18	17	25	30
60–64	7	11	12	14	20
≥ 65	6	11	7	15	16
Race/ethnicity
American Indian/Alaska Native	0	2	1	4	5
Asian^b	0	2	1	3	2
Black/African American	45	46	69	106	99
Hispanic/Latino^c	36	34	33	52	58
Native Hawaiian/other Pacific Islander	1	0	0	1	0
White	18	21	24	23	26
Multiracial	8	13	17	18	25
Exposure category^d
Sexual contact^e	79	78	99	144	159
Injection drug use^f	0	0	1	2	0
Sexual contact^e and injection drug use^f	26	38	39	56	49
Other^g	3	2	6	5	7
Region of residence^h
Northeast	26	32	39	61	56
Midwest	11	11	22	22	27
South	41	43	55	72	75
West	30	32	29	52	57
Subtotal	108	118	145	207	215
Transgender man^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	1	0
25–29	0	0	1	1	0
30–34	1	0	0	1	0
35–39	0	0	0	1	0
40–44	0	0	0	2	0
45–49	1	2	0	1	0
50–54	0	1	1	0	0
55–59	2	1	1	1	1
60–64	0	0	2	1	1
≥ 65	1	1	0	1	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	3	0	1	3	1
Hispanic/Latino^c	1	2	2	2	1
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	0	2	1	2	0
Multiracial	1	1	1	3	0
Exposure category^d
Sexual contact^e	3	0	3	6	0
Injection drug use^f	0	0	0	0	0
Sexual contact^e and injection drug use^f	2	5	1	4	2
Other^g	0	0	1	0	0
Region of residence^h
Northeast	1	0	1	2	1
Midwest	0	1	1	1	0
South	3	3	3	4	1
West	1	1	0	3	0
Subtotal	5	5	5	10	2
Additional gender identityⁱ
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	0	0
25–29	0	0	0	0	0
30–34	2	0	0	0	0
35–39	0	0	0	0	0
40–44	0	0	1	0	0
45–49	0	0	0	0	0
50–54	0	0	0	0	0
55–59	1	1	0	0	0
60–64	0	0	0	0	1
≥ 65	0	0	1	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	1	0	2	0	0
Hispanic/Latino^c	1	1	0	0	0
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	1	0	0	0	0
Multiracial	0	0	0	0	1
Exposure category^d
Sexual contact^e	2	0	1	0	1
Injection drug use^f	0	0	0	0	0
Sexual contact^e and injection drug use^f	1	1	1	0	0
Other^g	0	0	0	0	0
Region of residence^h
Northeast	1	0	1	0	1
Midwest	1	0	1	0	0
South	1	0	0	0	0
West	0	1	0	0	0
Subtotal	3	1	2	0	1
Total	116	124	152	217	218

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^c Hispanic/Latino persons can be of any race.
^d Risk factor data for transgender and additional gender identity persons aged ≥13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
ⁱ Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 14b. Deaths (any cause) of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
Transgender woman^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	2	1	5	7	5
25–29	8	12	17	17	12
30–34	9	9	19	30	41
35–39	16	13	17	29	30
40–44	12	12	17	23	27
45–49	19	12	18	26	15
50–54	12	19	17	22	20
55–59	19	18	17	25	30
60–64	7	11	12	14	20
≥ 65	6	12	8	15	16
Race/ethnicity
American Indian/Alaska Native	0	2	1	4	5
Asian^b	0	2	1	3	2
Black/African American	45	46	69	106	99
Hispanic/Latino^c	38	35	35	53	59
Native Hawaiian/other Pacific Islander	1	0	0	1	0
White	18	21	24	23	26
Multiracial	8	13	17	18	25
Exposure category^d
Sexual contact^e	79	79	99	145	159
Injection drug use^f	0	0	1	2	0
Sexual contact^e and injection drug use^f	28	38	41	56	50
Other^g	3	2	6	5	7
Region of residence^h
Northeast	26	32	39	61	56
Midwest	11	11	22	22	27
South	41	43	55	72	75
West	30	32	29	52	57
US dependent areas	2	1	2	1	1
Subtotal	110	119	147	208	216
Transgender man^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	1	0
25–29	0	0	1	1	0
30–34	1	0	0	1	0
35–39	0	0	0	1	0
40–44	0	0	0	2	0
45–49	1	2	0	1	0
50–54	0	1	1	0	0
55–59	2	1	1	1	1
60–64	0	0	2	1	1
≥ 65	1	1	0	1	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	3	0	1	3	1
Hispanic/Latino^c	1	2	2	2	1
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	0	2	1	2	0
Multiracial	1	1	1	3	0
Exposure category^d
Sexual contact^e	3	0	3	6	0
Injection drug use^f	0	0	0	0	0
Sexual contact^e and injection drug use^f	2	5	1	4	2
Other^g	0	0	1	0	0
Region of residence^h
Northeast	1	0	1	2	1
Midwest	0	1	1	1	0
South	3	3	3	4	1
West	1	1	0	3	0
US dependent areas	0	0	0	0	0
Subtotal	5	5	5	10	2
Additional gender identityⁱ
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	0	0
25–29	0	0	0	0	0
30–34	2	0	0	0	0
35–39	0	0	0	0	0
40–44	0	0	1	0	0
45–49	0	0	0	0	0
50–54	0	0	0	0	0
55–59	1	1	0	0	0
60–64	0	0	0	0	1
≥ 65	0	0	1	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	1	0	2	0	0
Hispanic/Latino^c	1	1	0	0	0
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	1	0	0	0	0
Multiracial	0	0	0	0	1
Exposure category^d
Sexual contact^e	2	0	1	0	1
Injection drug use^f	0	0	0	0	0
Sexual contact^e and injection drug use^f	1	1	1	0	0
Other^g	0	0	0	0	0
Region of residence^h
Northeast	1	0	1	0	1
Midwest	1	0	1	0	0
South	1	0	0	0	0
West	0	1	0	0	0
US dependent areas	0	0	0	0	0
Subtotal	3	1	2	0	1
Total	118	125	154	218	219

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^c Hispanic/Latino persons can be of any race.
^d Risk factor data for transgender and additional gender identity persons aged ≥13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
ⁱ Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	749,255	—	767,894	—	785,712	—	796,670	—	812,192	—
Female	235,211	—	238,870	—	242,488	—	243,646	—	246,029	—
Transgender woman/girl^b	10,775	—	11,347	—	11,937	—	12,447	—	13,111	—
Transgender man/boy^b	401	—	448	—	490	—	520	—	574	—
Additional gender identity^c	239	—	260	—	292	—	315	—	361	—
Age at end of year
< 13	2,058	3.9	1,897	3.6	1,670	3.2	1,445	2.8	1,262	2.4
13–14	670	8.1	667	8.0	652	7.8	639	7.3	599	6.7
15–19	4,548	21.5	4,367	20.7	4,251	20.2	3,800	17.6	3,689	17.1
20–24	28,433	128.9	27,005	123.7	26,064	120.4	24,267	113.0	23,768	110.4
25–29	70,343	301.1	70,846	300.9	69,328	294.5	65,558	287.5	62,673	279.9
30–34	82,697	376.6	87,652	396.0	93,088	414.4	97,085	424.4	100,758	436.1
35–39	91,538	432.0	93,448	433.7	95,421	438.6	96,667	434.8	100,231	449.5
40–44	95,663	488.7	96,353	489.5	97,899	491.4	100,213	484.8	102,963	487.9
45–49	129,431	619.4	122,787	592.7	116,648	572.1	108,962	536.3	104,701	529.3
50–54	162,116	760.0	156,876	752.2	150,087	733.2	144,716	696.3	138,428	662.1
55–59	143,636	654.5	152,013	693.6	159,310	728.4	162,057	735.4	162,000	751.1
60–64	95,574	479.6	103,683	510.7	111,536	542.5	119,583	568.4	127,237	599.2
≥ 65	89,174	175.7	101,225	193.3	114,965	212.8	128,606	236.2	143,958	257.8
Race/ethnicity
American Indian/Alaska Native	2,759	115.1	2,882	119.6	3,020	124.7	3,130	128.0	3,276	133.6
Asian^d	13,730	74.8	14,605	78.0	15,360	80.5	15,974	81.9	16,720	84.9
Black/African American	403,102	993.1	412,368	1008.3	421,362	1022.9	426,145	1,021.3	432,958	1,034.3
Hispanic/Latino^e	226,093	387.1	234,034	393.5	242,008	400.6	247,235	399.5	255,281	407.5
Native Hawaiian/other Pacific Islander	745	127.9	790	133.1	836	138.4	889	143.7	955	152.5
White	292,874	148.1	297,228	150.5	301,145	152.7	303,326	153.4	306,583	155.8
Multiracial	55,893	798.0	56,227	781.8	56,507	766.1	56,219	737.5	55,816	716.4
Transmission category^f
Male sex at birth (≥ 13 yrs at end of year)^g
Male-to-male sexual contact^h	549,064	—	567,472	—	585,215	—	598,237	—	615,019	—
Injection drug useⁱ	67,773	—	67,101	—	66,494	—	65,327	—	64,530	—
Male-to-male sexual contact^h and injection drug useⁱ	58,001	—	58,116	—	58,324	—	57,858	—	57,559	—
Heterosexual contact^j	76,847	—	78,210	—	79,292	—	79,440	—	79,991	—
Perinatal^k	4,814	—	4,912	—	5,037	—	5,120	—	5,217	—
Other^l	2,767	—	2,753	—	2,755	—	2,737	—	2,733	—
Subtotal	759,266	570.1	778,564	580.6	797,117	590.5	808,719	588.8	825,049	598.1
Female sex at birth (≥ 13 yrs at end of year)^g
Injection drug useⁱ	49,011	—	48,850	—	48,759	—	48,197	—	47,864	—
Heterosexual contact^j	178,387	—	182,152	—	185,832	—	187,561	—	190,265	—
Perinatal^k	5,518	—	5,697	—	5,858	—	5,979	—	6,120	—
Other^l	1,641	—	1,659	—	1,684	—	1,697	—	1,707	—
Subtotal	234,557	168.5	238,358	170.0	242,132	171.6	243,434	171.9	245,956	172.9
Child (< 13 yrs at end of year)
Perinatal	1,713	—	1,562	—	1,382	—	1,209	—	1,060	—
Other^l	345	—	335	—	288	—	236	—	202	—
Subtotal	2,058	3.9	1,897	3.6	1,670	3.2	1,445	2.8	1,262	2.4
Region of residence^m
Northeast	231,318	412.5	233,355	416.1	234,829	419.3	234,339	407.4	235,158	411.4
Midwest	118,715	174.2	121,808	178.4	124,536	182.2	126,494	183.5	129,138	187.6
South	449,380	363.5	461,770	370.5	474,428	377.5	482,397	381.6	493,509	387.9
West	196,468	254.3	201,886	259.4	207,126	264.5	210,368	267.5	214,462	272.6
Totalⁿ	995,881	306.3	1,018,819	311.7	1,040,919	317.0	1,053,598	317.8	1,072,267	323.1

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Data include transgender and additional gender identity persons.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^m Data are based on residence at the end of the specified year (i.e., most recent known address).
ⁿ Includes persons whose race/ethnicity is unknown.

Table 15b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	760,803	—	779,369	—	797,263	—	808,207	—	823,824	—
Female	240,162	—	243,758	—	247,371	—	248,484	—	250,857	—
Transgender woman/girl^b	10,814	—	11,385	—	11,978	—	12,491	—	13,150	—
Transgender man/boy^b	404	—	451	—	493	—	523	—	577	—
Additional gender identity^c	239	—	261	—	292	—	315	—	361	—
Age at end of year
< 13	2,067	3.9	1,903	3.6	1,675	3.2	1,448	2.7	1,266	2.4
13–14	676	8.1	675	8.0	656	7.8	642	7.2	601	6.7
15–19	4,594	21.5	4,410	20.7	4,277	20.1	3,822	17.6	3,707	17.0
20–24	28,729	128.7	27,275	123.6	26,319	120.2	24,487	112.8	23,959	110.0
25–29	71,050	300.9	71,544	300.7	70,016	294.3	66,172	287.0	63,270	279.4
30–34	83,610	377.1	88,530	396.4	93,994	414.6	97,999	424.2	101,666	435.7
35–39	92,825	433.4	94,626	434.8	96,498	439.3	97,690	435.3	101,254	449.9
40–44	97,251	491.0	97,870	491.7	99,356	493.3	101,638	486.4	104,375	489.3
45–49	131,618	622.6	124,765	595.6	118,507	574.7	110,642	538.4	106,287	531.2
50–54	165,046	764.7	159,691	756.8	152,693	737.3	147,229	700.3	140,770	665.7
55–59	146,286	659.2	154,756	698.4	162,214	733.5	164,931	740.0	164,852	755.6
60–64	97,425	483.3	105,704	514.8	113,673	546.8	121,871	572.7	129,622	603.6
≥ 65	91,245	177.3	103,475	195.0	117,519	214.6	131,449	238.1	147,140	259.8
Race/ethnicity
American Indian/Alaska Native	2,761	—	2,884	—	3,022	—	3,132	—	3,278	—
Asian^d	13,786	—	14,665	—	15,427	—	16,041	—	16,788	—
Black/African American	403,402	—	412,682	—	421,683	—	426,472	—	433,293	—
Hispanic/Latino^e	242,128	—	249,919	—	257,943	—	263,102	—	271,212	—
Native Hawaiian/other Pacific Islander	778	—	822	—	869	—	923	—	989	—
White	292,960	—	297,313	—	301,240	—	303,423	—	306,688	—
Multiracial	55,919	—	56,251	—	56,529	—	56,244	—	55,839	—
Transmission category^f
Male sex at birth (≥ 13 yrs at end of year)^g
Male-to-male sexual contact^h	553,853	—	572,368	—	590,283	—	603,437	—	620,421	—
Injection drug useⁱ	71,241	—	70,441	—	69,734	—	68,468	—	67,586	—
Male-to-male sexual contact^h and injection drug usei	58,804	—	58,890	—	59,089	—	58,604	—	58,297	—
Heterosexual contact^j	79,212	—	80,556	—	81,654	—	81,781	—	82,317	—
Perinatal^k	4,943	—	5,040	—	5,166	—	5,245	—	5,337	—
Other^l	2,795	—	2,780	—	2,782	—	2,763	—	2,759	—
Subtotal	770,848	572.3	790,075	582.7	808,707	592.6	820,299	590.7	836,718	600.0
Female sex at birth (≥ 13 yrs at end of year)^g
Injection drug useⁱ	50,003	—	49,809	—	49,704	—	49,119	—	48,764	—
Heterosexual contact^j	182,209	—	185,953	—	189,650	—	191,356	—	194,074	—
Perinatal^k	5,641	—	5,813	—	5,966	—	6,090	—	6,227	—
Other^l	1,654	—	1,671	—	1,694	—	1,708	—	1,720	—
Subtotal	239,507	170.0	243,246	171.5	247,015	173.1	248,273	173.2	250,785	174.2
Child (< 13 yrs at end of year)
Perinatal	1,722	—	1,568	—	1,387	—	1,212	—	1,064	—
Other^l	345	—	335	—	288	—	236	—	202	—
Subtotal	2,067	3.9	1,903	3.6	1,675	3.2	1,448	2.7	1,266	2.4
Region of residence^m
Northeast	231,318	412.5	233,355	416.1	234,829	419.3	234,339	407.4	235,158	411.4
Midwest	118,715	174.2	121,808	178.4	124,536	182.2	126,494	183.5	129,138	187.6
South	449,380	363.5	461,770	370.5	474,428	377.5	482,397	381.6	493,509	387.9
West	196,468	254.3	201,886	259.4	207,126	264.5	210,368	267.5	214,462	272.6
U.S. dependent areas	16,541	444.2	16,405	456.8	16,478	459.0	16,422	446.6	16,502	451.1
Totalⁿ	1,012,422	307.9	1,035,224	313.3	1,057,397	318.6	1,070,020	319.2	1,088,769	324.5

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Data include transgender and additional gender identity persons.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^m Data are based on residence at the end of the specified year (i.e., most recent known address).
ⁿ Includes persons whose race/ethnicity is unknown.

Table 16a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2021—United States
	American Indian/Alaska Native		Asian^a		Black/African American		Hispanic/Latino^b		Native Hawaiian/other Pacific Islander		White		Multiracial		Total^c
	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d
Gender
Male	2,411	—	13,594	—	283,953	—	204,798	—	763	—	264,430	—	41,758	—	812,192	—
Female	796	—	2,890	—	142,524	—	45,945	—	153	—	40,562	—	12,966	—	246,029	—
Transgender woman/girl^e	64	—	219	—	6,106	—	4,311	—	39	—	1,370	—	1,002	—	13,111	—
Transgender man/boy^e	4	—	11	—	234	—	130	—	0	—	142	—	53	—	574	—
Additional gender identity^f	1	—	6	—	141	—	97	—	0	—	79	—	37	—	361	—
Age at end of year
< 13	6	1.5	88	3.1	731	10.2	180	1.3	3	2.6	155	0.6	99	3.9	1,262	2.4
13–14	1	1.3	39	8.7	338	27.5	81	3.5	0	0.0	88	2.0	52	13.7	599	6.7
15–19	19	10.5	108	9.5	2,171	74.2	766	14.3	8	18.5	417	3.7	200	24.4	3,689	17.1
20–24	88	48.7	376	30.9	13,224	437.5	5,909	119.1	27	63.2	3,118	27.4	1,021	143.8	23,768	110.4
25–29	270	142.5	1,160	79.5	30,983	946.5	16,750	344.7	71	150.0	10,225	85.6	3,208	518.2	62,673	279.9
30–34	394	210.5	1,860	110.0	47,548	1450.8	25,990	549.9	126	234.5	19,220	151.7	5,614	1131.0	100,758	436.1
35–39	391	237.9	1,953	116.1	42,427	1480.5	27,860	604.2	124	239.0	21,900	174.9	5,569	1393.7	100,231	449.5
40–44	380	252.1	2,038	134.2	41,304	1525.0	29,189	665.9	129	284.9	24,185	202.3	5,723	1667.4	102,963	487.9
45–49	318	229.1	2,348	161.6	41,266	1652.8	29,001	730.0	101	262.6	26,078	228.7	5,562	1979.5	104,701	529.3
50–54	458	317.7	2,290	175.1	51,427	1998.0	34,138	960.3	110	298.8	42,454	325.8	7,465	2901.8	138,428	662.1
55–59	397	258.3	1,771	151.8	58,932	2251.4	34,884	1135.0	100	280.9	57,324	401.3	8,440	3574.7	162,000	751.1
60–64	281	190.0	1,133	108.5	48,019	1961.2	24,471	995.8	73	231.2	46,754	314.0	6,359	2914.3	127,237	599.2
≥ 65	273	83.2	1,556	57.7	54,588	1034.4	26,062	516.2	83	122.6	54,665	130.3	6,504	1368.1	143,958	257.8
Transmission category^g
Male sex at birth (≥ 13 yrs at end of year)^h
Male-to-male sexual contactⁱ	1,773	—	11,670	—	192,625	—	159,035	—	683	—	217,222	—	31,683	—	615,019	—
Injection drug use^j	225	—	463	—	29,182	—	18,423	—	24	—	13,440	—	2,699	—	64,530	—
Male-to-male sexual contactⁱ and injection drug use^j	293	—	436	—	15,249	—	13,539	—	52	—	23,373	—	4,573	—	57,559	—
Heterosexual contact^k	164	—	1,078	—	49,028	—	16,450	—	37	—	9,915	—	3,292	—	79,991	—
Perinatal^l	6	—	66	—	2,969	—	1,241	—	3	—	574	—	350	—	5,217	—
Other^m	14	—	67	—	793	—	430	—	1	—	1,274	—	150	—	2,733	—
Subtotal	2,474	247.3	13,780	172.7	289,847	1756.8	209,118	839.6	800	309.7	265,798	313.6	42,747	1673.0	825,049	598.1
Female sex at birth (≥ 13 yrs at end of year)^h
Injection drug use^j	270	—	192	—	22,134	—	9,349	—	27	—	12,783	—	3,047	—	47,864	—
Heterosexual contact^k	509	—	2,511	—	115,867	—	34,984	—	125	—	26,736	—	9,416	—	190,265	—
Perinatal^l	9	—	77	—	3,584	—	1,384	—	0	—	638	—	419	—	6,120	—
Other^m	8	—	71	—	795	—	267	—	1	—	473	—	87	—	1,707	—
Subtotal	796	76.5	2,852	32.3	142,380	781.6	45,983	188.6	152	59.9	40,630	46.8	12,970	483.6	245,956	172.9
Child (< 13 yrs at end of year)
Perinatal	5	—	51	—	621	—	165	—	3	—	124	—	91	—	1,060	—
Other^m	1	—	37	—	110	—	15	—	0	—	31	—	8	—	202	—
Subtotal	6	1.5	88	3.1	731	10.2	180	1.3	3	2.6	155	0.6	99	3.9	1,262	2.4
Region of residenceⁿ
Northeast	145	109.0	3,571	88.2	88,954	1,366.9	73,702	840.5	66	284.4	53,270	145.5	15,118	1,428.2	235,158	411.4
Midwest	417	99.4	1,618	65.8	54,575	747.9	16,755	287.0	52	126.7	48,522	94.6	7,116	476.1	129,138	187.6
South	803	97.3	3,600	75.3	255,815	1,047.8	89,718	375.2	167	161.2	119,022	168.7	24,228	926.4	493,509	387.9
West	1,911	177.9	7,931	94.5	33,614	923.7	75,106	311.3	670	146.2	85,769	223.6	9,354	356.7	214,462	272.6
Total	3,276	133.6	16,720	84.9	432,958	1034.3	255,281	407.5	955	152.5	306,583	155.8	55,816	716.4	1,072,267	323.1

Note: Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^b Hispanic/Latino persons can be of any race.
^c Includes persons whose race/ethnicity is unknown.
^d Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^e “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^h Data include transgender and additional gender identity persons.
ⁱ Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^j Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^k Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^l Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^m Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁿ Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 16b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2021—United States and 6 dependent areas
	American Indian/Alaska Native	Asian^a	Black/African American	Hispanic/Latino^b	Native Hawaiian/other Pacific Islander	White	Multiracial	Total^c
	No.	No.	No.	No.	No.	No.	No.	No.
Gender
Male	2,413	13,651	284,157	216,034	789	264,516	41,776	823,824
Female	796	2,901	142,655	50,599	160	40,581	12,971	250,857
Transgender woman/girl^d	64	219	6,106	4,349	40	1,370	1,002	13,150
Transgender man/boy^d	4	11	234	133	0	142	53	577
Additional gender identity^e	1	6	141	97	0	79	37	361
Age at end of year
< 13	6	88	732	182	4	155	99	1,266
13–14	1	39	338	83	0	88	52	601
15–19	19	108	2,173	781	8	417	201	3,707
20–24	88	376	13,230	6,092	28	3,118	1,022	23,959
25–29	270	1,160	30,988	17,338	73	10,226	3,209	63,270
30–34	394	1,867	47,563	26,864	132	19,226	5,614	101,666
35–39	391	1,960	42,444	28,844	128	21,911	5,569	101,254
40–44	380	2,046	41,326	30,555	135	24,191	5,727	104,375
45–49	318	2,356	41,303	30,531	102	26,086	5,563	106,287
50–54	459	2,296	51,485	36,388	114	42,471	7,470	140,770
55–59	397	1,781	58,982	37,651	103	57,343	8,443	164,852
60–64	282	1,147	48,064	26,772	77	46,773	6,360	129,622
≥ 65	273	1,564	54,665	29,131	85	54,683	6,510	147,140
Transmission category^f
Male sex at birth (≥ 13 yrs at end of year)^g
Male-to-male sexual contact^h	1,774	11,716	192,718	164,187	704	217,295	31,698	620,421
Injection drug useⁱ	225	469	29,219	21,432	24	13,444	2,700	67,586
Male-to-male sexual contact^h and injection drug useⁱ	293	438	15,255	14,260	54	23,379	4,575	58,297
Heterosexual contact^j	165	1,082	49,093	18,700	40	9,919	3,293	82,317
Perinatal^k	6	66	2,971	1,358	3	574	350	5,337
Other_l	14	67	793	455	1	1,274	150	2,759
Subtotal	2,476	13,837	290,050	220,391	827	265,884	42,765	836,718
Female sex at birth (≥ 13 yrs at end of year)^g
Injection drug useⁱ	270	194	22,149	10,225	27	12,789	3,048	48,764
Heterosexual contact^j	509	2,520	115,977	38,653	130	26,748	9,419	194,074
Perinatal^k	9	77	3,589	1,485	1	638	421	6,227
Other^l	8	71	797	277	1	473	87	1,720
Subtotal	796	2,863	142,511	50,639	158	40,649	12,975	250,785
Child (< 13 yrs at end of year)
Perinatal	5	51	622	167	4	124	91	1,064
Other^l	1	37	110	15	0	31	8	202
Subtotal	6	88	732	182	4	155	99	1,266
Region of residence^m
Northeast	145	3,571	88,954	73,702	66	53,270	15,118	235,158
Midwest	417	1,618	54,575	16,755	52	48,522	7,116	129,138
South	803	3,600	255,815	89,718	167	119,022	24,228	493,509
West	1,911	7,931	33,614	75,106	670	85,769	9,354	214,462
U.S. dependent areas	2	68	335	15,931	34	105	23	16,502
Total	3,278	16,788	433,293	271,212	989	306,688	55,839	1,088,769

Note: Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^b Hispanic/Latino persons can be of any race.
^c Includes persons whose race/ethnicity is unknown.
^d “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^e Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Data include transgender and additional gender identity persons.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^m Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 17a. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, assigned sex at birth, and selected characteristics, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at end of year
13–14	301	7.1	298	7.0	308	7.2	311	6.9	300	6.6
15–19	2,983	27.7	2,883	26.8	2,858	26.6	2,500	22.7	2,415	21.9
20–24	23,174	204.8	22,111	197.9	21,436	193.7	20,106	183.7	19,861	181.0
25–29	58,974	495.7	59,659	496.7	58,647	487.9	55,563	479.8	53,173	467.3
30–34	66,180	597.2	71,477	639.0	76,816	675.6	80,964	699.6	84,810	726.5
35–39	67,930	641.0	70,429	653.2	73,075	670.9	75,449	672.1	79,475	705.6
40–44	67,581	695.4	68,345	698.7	70,274	709.4	72,880	702.9	75,872	716.2
45–49	94,975	917.6	89,349	871.8	83,910	832.2	77,639	764.4	74,209	751.4
50–54	124,484	1,187.2	119,594	1,165.3	113,494	1,125.7	108,467	1,046.0	102,890	985.9
55–59	110,421	1,034.8	117,086	1,098.5	122,778	1,154.0	124,826	1,149.7	124,456	1,170.8
60–64	73,334	769.6	79,273	815.8	85,115	864.0	91,286	892.2	97,331	941.9
≥ 65	68,929	306.1	78,060	335.4	88,406	367.4	98,728	402.4	110,257	437.3
Race/ethnicity
American Indian/Alaska Native	2,031	212.1	2,139	221.4	2,252	231.0	2,353	237.2	2,474	247.3
Asian^c	11,210	153.0	11,965	159.7	12,605	164.8	13,127	166.7	13,780	172.7
Black/African American	265,465	1,686.5	272,692	1,715.9	279,785	1,743.9	284,122	1,734.2	289,847	1,756.8
Hispanic/Latino^d	182,348	805.4	189,522	818.7	196,749	832.8	201,717	825.6	209,118	839.6
Native Hawaiian/other Pacific Islander	619	261.2	662	273.6	706	286.0	744	292.6	800	309.7
White	254,576	302.8	258,273	307.2	261,441	310.9	263,168	309.8	265,798	313.6
Multiracial	42,527	1,929.5	42,821	1,877.2	43,092	1,824.8	43,002	1,742.0	42,747	1,673.0
Transmission category^e
Male-to-male sexual contact^f	549,064	—	567,472	—	585,215	—	598,237	—	615,019	—
Injection drug use^g	67,773	—	67,101	—	66,494	—	65,327	—	64,530	—
Male-to-male sexual contact^f and injection drug use^g	58,001	—	58,116	—	58,324	—	57,858	—	57,559	—
Heterosexual contact^h	76,847	—	78,210	—	79,292	—	79,440	—	79,991	—
Perinatalⁱ	4,814	—	4,912	—	5,037	—	5,120	—	5,217	—
Other^j	2,767	—	2,753	—	2,755	—	2,737	—	2,733	—
Region of residence^k
Northeast	163,299	707.0	165,156	714.1	166,690	720.8	166,706	696.6	167,785	703.6
Midwest	93,749	335.1	96,200	342.8	98,302	349.3	99,911	349.3	102,097	356.3
South	330,995	660.0	341,278	673.9	351,614	687.4	358,763	692.2	368,312	704.1
West	171,223	536.0	175,930	545.1	180,511	554.3	183,339	556.0	186,855	564.0
Subtotal	759,266	570.1	778,564	580.6	797,117	590.5	808,719	588.8	825,049	598.1
Female sex at birth^b
Age at end of year
13–14	369	9.1	369	9.1	344	8.4	328	7.7	299	6.9
15–19	1,565	15.2	1,484	14.4	1,393	13.5	1,300	12.3	1,274	12.1
20–24	5,259	48.9	4,894	45.9	4,628	43.8	4,161	39.5	3,907	37.0
25–29	11,369	99.2	11,187	97.0	10,681	92.7	9,995	89.0	9,500	86.3
30–34	16,517	151.9	16,175	147.8	16,272	146.7	16,121	142.6	15,948	139.5
35–39	23,608	222.8	23,019	213.8	22,346	205.7	21,218	192.8	20,756	188.1
40–44	28,082	284.9	28,008	282.9	27,625	275.9	27,333	265.3	27,091	257.7
45–49	34,456	326.7	33,438	319.5	32,738	317.6	31,323	308.3	30,492	307.8
50–54	37,632	347.0	37,282	351.9	36,593	352.3	36,249	348.1	35,538	339.4
55–59	33,215	294.6	34,927	310.2	36,532	325.2	37,231	333.1	37,544	343.3
60–64	22,240	213.9	24,410	230.6	26,421	246.7	28,297	261.8	29,906	274.3
≥ 65	20,245	71.7	23,165	79.7	26,559	88.6	29,878	99.9	33,701	110.0
Race/ethnicity
American Indian/Alaska Native	722	72.1	737	72.9	762	74.6	770	74.7	796	76.5
Asian^c	2,406	29.2	2,531	30.0	2,646	30.8	2,747	31.5	2,852	32.3
Black/African American	136,404	774.3	138,566	779.5	140,606	783.8	141,187	780.4	142,380	781.6
Hispanic/Latino^d	43,472	194.8	44,258	193.7	45,035	193.0	45,323	189.6	45,983	188.6
Native Hawaiian/other Pacific Islander	123	52.4	126	52.6	128	52.4	142	56.9	152	59.9
White	38,048	43.5	38,714	44.3	39,494	45.2	39,976	45.9	40,630	46.8
Multiracial	13,187	561.8	13,231	546.0	13,267	530.3	13,095	504.2	12,970	483.6
Transmission category^e
Injection drug use^g	49,011	—	48,850	—	48,759	—	48,198	—	47,864	—
Heterosexual contact^h	178,387	—	182,152	—	185,832	—	187,561	—	190,265	—
Perinatalⁱ	5,518	—	5,697	—	5,858	—	5,979	—	6,120	—
Other^j	1,641	—	1,659	—	1,684	—	1,697	—	1,707	—
Region of residence^k
Northeast	67,699	274.2	67,927	275.0	67,894	275.0	67,428	267.8	67,192	268.0
Midwest	24,497	84.2	25,146	86.2	25,835	88.3	26,233	89.5	26,742	91.1
South	117,446	221.6	119,631	223.4	122,055	225.6	122,969	227.2	124,610	227.9
West	24,915	76.8	25,654	78.3	26,348	79.7	26,804	81.2	27,412	82.6
Subtotal	234,557	168.5	238,358	170.0	242,132	171.6	243,434	171.9	245,956	172.9
Total	993,823	364.8	1,016,922	370.8	1,039,249	376.5	1,052,153	377.1	1,071,005	382.2

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
^b Data include transgender and additional gender identity persons.
^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 17b. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, assigned sex at birth, and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017		2018		2019		2020 (COVID-19 Pandemic)		2021
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at end of year
13–14	303	7.1	302	7.0	311	7.2	313	6.9	301	6.6
15–19	3,007	27.6	2,911	26.7	2,875	26.4	2,514	22.6	2,426	21.8
20–24	23,402	204.4	22,314	197.5	21,639	193.4	20,287	183.2	20,013	180.3
25–29	59,536	495.2	60,224	496.4	59,207	487.5	56,059	478.8	53,671	466.5
30–34	66,862	597.8	72,149	639.4	77,522	675.7	81,692	699.3	85,548	725.7
35–39	68,831	642.9	71,261	654.7	73,861	671.9	76,221	673.0	80,259	706.4
40–44	68,666	698.6	69,398	701.9	71,300	712.2	73,877	705.2	76,866	718.3
45–49	96,474	921.8	90,669	875.1	85,137	835.3	78,767	767.1	75,282	754.0
50–54	126,550	1,193.5	121,608	1,171.9	115,351	1,131.4	110,249	1,051.6	104,521	990.7
55–59	112,232	1,040.7	118,983	1,104.6	124,796	1,160.7	126,831	1,155.8	126,481	1,177.0
60–64	74,637	774.7	80,658	821.1	86,562	869.3	92,826	897.6	98,927	947.3
≥ 65	70,348	308.2	79,598	337.5	90,146	369.8	100,663	404.8	112,423	439.9
Race/ethnicity
American Indian/Alaska Native	2,033	—	2,141	—	2,254	—	2,355	—	2,476	—
Asian^c	11,255	—	12,014	—	12,661	—	13,183	—	13,837	—
Black/African American	265,638	—	272,879	—	279,975	—	284,317	—	290,050	—
Hispanic/Latino^d	193,594	—	200,681	—	207,968	—	212,915	—	220,391	—
Native Hawaiian/other Pacific Islander	644	—	688	—	732	—	771	—	827	—
White	254,644	—	258,341	—	261,518	—	263,248	—	265,884	—
Multiracial	42,548	—	42,839	—	43,110	—	43,022	—	42,765	—
Transmission category^e
Male-to-male sexual contact^f	553,853	—	572,368	—	590,282	—	603,437	—	620,421	—
Injection drug use^g	71,241	—	70,441	—	69,734	—	68,468	—	67,586	—
Male-to-male sexual contact^f and injection drug use^g	58,805	—	58,890	—	59,089	—	58,605	—	58,297	—
Heterosexual contact^h	79,212	—	80,556	—	81,654	—	81,781	—	82,317	—
Perinatalⁱ	4,943	—	5,040	—	5,166	—	5,245	—	5,337	—
Other^j	2,795	—	2,780	—	2,782	—	2,763	—	2,759	—
Region of residence^k
Northeast	163,299	707.0	165,156	714.1	166,690	720.8	166,706	696.6	167,785	703.6
Midwest	93,749	335.1	96,200	342.8	98,302	349.3	99,911	349.3	102,097	356.3
South	330,995	660.0	341,278	673.9	351,614	687.4	358,763	692.2	368,312	704.1
West	171,223	536.0	175,930	545.1	180,511	554.3	183,339	556.0	186,855	564.0
U.S. dependent areas	11,582	765.7	11,511	782.4	11,590	784.3	11,580	761.2	11,669	767.5
Subtotal	770,848	572.3	790,075	582.7	808,707	592.6	820,299	590.7	836,718	600.0
Female sex at birth^b
Age at end of year
13–14	373	9.1	373	9.1	345	8.4	329	7.6	300	6.9
15–19	1,587	15.2	1,499	14.4	1,402	13.4	1,308	12.3	1,281	12.0
20–24	5,327	49.0	4,961	46.0	4,680	43.7	4,200	39.5	3,946	37.0
25–29	11,514	99.3	11,320	97.1	10,809	92.8	10,113	89.1	9,599	86.2
30–34	16,748	152.4	16,381	148.2	16,472	147.1	16,307	142.8	16,118	139.6
35–39	23,994	223.9	23,365	214.7	22,637	206.3	21,469	193.1	20,995	188.4
40–44	28,585	286.5	28,472	284.2	28,056	277.0	27,761	266.4	27,509	258.8
45–49	35,144	329.3	34,096	322.0	33,370	320.0	31,875	310.0	31,005	309.3
50–54	38,496	350.6	38,083	355.2	37,342	355.2	36,980	350.8	36,249	342.1
55–59	34,054	298.6	35,773	314.1	37,418	329.3	38,100	336.7	38,371	346.6
60–64	22,788	216.5	25,046	233.9	27,111	250.3	29,045	265.5	30,695	278.2
≥ 65	20,897	73.0	23,877	81.0	27,373	90.1	30,786	101.5	34,717	111.7
Race/ethnicity
American Indian/Alaska Native	722	—	737	—	762	—	770	—	796	—
Asian^c	2,417	—	2,542	—	2,657	—	2,758	—	2,863	—
Black/African American	136,530	—	138,692	—	140,736	—	141,318	—	142,511	—
Hispanic/Latino^d	48,254	—	48,980	—	49,748	—	49,991	—	50,639	—
Native Hawaiian/other Pacific Islander	130	—	131	—	134	—	148	—	158	—
White	38,066	—	38,731	—	39,512	—	39,993	—	40,649	—
Multiracial	13,192	—	13,237	—	13,271	—	13,100	—	12,975	—
Transmission category^e
Injection drug use^g	50,003	—	49,809	—	49,704	—	49,119	—	48,764	—
Heterosexual contact^h	182,209	—	185,953	—	189,650	—	191,356	—	194,074	—
Perinatalⁱ	5,641	—	5,813	—	5,966	—	6,090	—	6,227	—
Other^j	1,654	—	1,671	—	1,694	—	1,708	—	1,720	—
Region of residence^k
Northeast	67,699	274.2	67,927	275.0	67,894	275.0	67,428	267.8	67,192	268.0
Midwest	24,497	84.2	25,146	86.2	25,835	88.3	26,233	89.5	26,742	91.1
South	117,446	221.6	119,631	223.4	122,055	225.6	122,969	227.2	124,610	227.9
West	24,915	76.8	25,654	78.3	26,348	79.7	26,804	81.2	27,412	82.6
U.S. dependent areas	4,950	294.0	4,888	298.7	4,883	296.8	4,839	285.1	4,829	284.1
Subtotal	239,507	170.0	243,246	171.5	247,015	173.1	248,273	173.2	250,785	174.2
Total	1,010,355	366.6	1,033,321	372.5	1,055,722	378.1	1,068,572	378.7	1,087,503	383.7

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
^b Data include transgender and additional gender identity persons.
^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 18a. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
Transgender woman^a
Age at end of year
13–14	0	0	0	1	2
15–19	106	78	76	53	64
20–24	864	837	802	774	786
25–29	2,002	2,005	1,928	1,846	1,833
30–34	1,891	2,115	2,380	2,620	2,749
35–39	1,519	1,628	1,758	1,840	2,015
40–44	1,150	1,227	1,314	1,451	1,605
45–49	1,117	1,132	1,173	1,168	1,191
50–54	1,010	1,056	1,055	1,105	1,123
55–59	625	703	795	830	876
60–64	314	355	392	455	521
≥ 65	175	209	262	303	345
Race/ethnicity
American Indian/Alaska Native	44	51	55	59	64
Asian^b	166	176	188	201	219
Black/African American	5,029	5,305	5,581	5,816	6,106
Hispanic/Latino^c	3,436	3,642	3,870	4,062	4,311
Native Hawaiian/other Pacific Islander	24	27	31	33	39
White	1,124	1,174	1,232	1,284	1,370
Multiracial	950	970	978	991	1,001
Exposure category^d
Sexual contact^e	8,923	9,467	10,027	10,529	11,151
Injection drug use^f	22	26	27	27	30
Sexual contact^e and injection drug use^f	1,646	1,663	1,682	1,670	1,679
Perinatal^g	24	24	23	23	22
Other^h	158	165	176	197	228
Region of residenceⁱ
Northeast	2,786	2,928	3,039	3,126	3,256
Midwest	1,497	1,601	1,655	1,741	1,862
South	3,937	4,114	4,339	4,577	4,830
West	2,553	2,702	2,902	3,002	3,162
Subtotal	10,773	11,345	11,935	12,446	13,110
Transgender man^a
Age at end of year
13–14	1	0	0	1	2
15–19	7	7	5	3	6
20–24	20	22	29	39	40
25–29	63	75	75	69	70
30–34	45	63	88	99	123
35–39	66	66	67	76	83
40–44	41	51	55	56	62
45–49	49	52	53	48	48
50–54	48	47	45	48	47
55–59	28	25	34	39	45
60–64	21	27	23	25	23
≥ 65	11	12	15	17	25
Race/ethnicity
American Indian/Alaska Native	4	4	4	4	4
Asian^b	6	8	9	9	11
Black/African American	175	194	210	217	234
Hispanic/Latino^c	87	96	109	117	130
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	86	102	110	123	142
Multiracial	42	43	47	50	53
Exposure category^d
Sexual contact^e	291	334	367	390	437
Injection drug use^f	6	8	9	10	10
Sexual contact^e and injection drug use^f	65	63	65	66	65
Perinatal^g	18	18	17	19	19
Other^h	20	24	31	35	43
Region of residenceⁱ
Northeast	77	80	89	94	101
Midwest	112	122	127	129	136
South	119	136	153	176	198
West	92	109	120	121	139
Subtotal	400	447	489	520	574
Additional gender identity^j
Age at end of year
13–14	0	0	0	0	0
15–19	3	5	6	4	4
20–24	26	30	39	36	49
25–29	46	47	46	53	65
30–34	34	41	58	69	73
35–39	34	38	41	38	39
40–44	21	20	18	24	33
45–49	27	26	26	32	33
50–54	17	18	21	19	22
55–59	16	17	18	14	16
60–64	9	10	8	14	14
≥ 65	6	8	11	12	13
Race/ethnicity
American Indian/Alaska Native	0	1	1	1	1
Asian^b	2	5	5	6	6
Black/African American	102	109	118	128	141
Hispanic/Latino^c	63	67	76	81	97
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	45	49	58	64	79
Multiracial	27	29	34	35	37
Exposure category^d
Sexual contact^e	203	225	255	275	314
Injection drug use^f	1	1	1	1	1
Sexual contact^e and injection drug use^f	28	27	28	29	34
Perinatal^g	3	3	3	3	3
Other^h	4	4	5	7	9
Region of residenceⁱ
Northeast	110	129	138	143	155
Midwest	37	40	52	59	67
South	72	72	79	81	90
West	20	19	23	32	49
Subtotal	239	260	292	315	361
Total	11,412	12,052	12,716	13,281	14,045

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^c Hispanic/Latino persons can be of any race.
^d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
ⁱ Data are based on address of residence at the end of the specified year (i.e., most recent known address).
^j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 18b. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017	2018	2019	2020 (COVID-19 Pandemic)	2021
	No.	No.	No.	No.	No.
Transgender woman^a
Age at end of year
13–14	0	0	0	1	2
15–19	106	78	76	53	64
20–24	867	841	807	780	789
25–29	2,005	2,008	1,931	1,848	1,838
30–34	1,900	2,124	2,388	2,627	2,754
35–39	1,524	1,631	1,761	1,846	2,018
40–44	1,153	1,234	1,322	1,460	1,614
45–49	1,120	1,132	1,174	1,170	1,193
50–54	1,014	1,058	1,059	1,107	1,124
55–59	631	710	801	836	881
60–64	315	356	394	458	525
≥ 65	177	211	263	304	347
Race/ethnicity
American Indian/Alaska Native	44	51	55	59	64
Asian^b	166	176	188	201	219
Black/African American	5,030	5,306	5,582	5,817	6,106
Hispanic/Latino^c	3,474	3,679	3,908	4,104	4,349
Native Hawaiian/other Pacific Islander	24	27	32	34	40
White	1,124	1,174	1,233	1,284	1,370
Multiracial	950	970	978	991	1,001
Exposure category^d
Sexual contact^e	8,954	9,498	10,062	10,567	11,185
Injection drug use^f	22	26	27	27	30
Sexual contact^e and injection drug use^f	1,654	1,670	1,688	1,676	1,684
Perinatal^g	24	24	23	23	22
Other^h	158	165	176	197	228
Region of residenceⁱ
Northeast	2,786	2,928	3,039	3,126	3,256
Midwest	1,497	1,601	1,655	1,741	1,862
South	3,937	4,114	4,339	4,577	4,830
West	2,553	2,702	2,902	3,002	3,162
US dependent areas	39	38	41	44	39
Subtotal	10,812	11,383	11,976	12,490	13,149
Transgender man^a
Age at end of year
13–14	1	0	0	1	2
15–19	8	8	5	3	6
20–24	20	22	30	40	41
25–29	64	76	76	69	70
30–34	45	63	88	100	124
35–39	66	66	67	76	83
40–44	41	51	55	56	62
45–49	49	52	53	48	48
50–54	48	47	45	48	47
55–59	28	25	34	39	45
60–64	21	27	23	25	23
≥ 65	12	13	16	18	26
Race/ethnicity
American Indian/Alaska Native	4	4	4	4	4
Asian^b	6	8	9	9	11
Black/African American	175	194	210	217	234
Hispanic/Latino^c	90	99	112	120	133
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	86	102	110	123	142
Multiracial	42	43	47	50	53
Exposure category^d
Sexual contact^e	292	335	368	391	438
Injection drug use^f	6	8	9	10	10
Sexual contact^e and injection drug use^f	66	64	66	67	66
Perinatal^g	19	19	18	20	20
Other^h	20	24	31	35	43
Region of residenceⁱ
Northeast	77	80	89	94	101
Midwest	112	122	127	129	136
South	119	136	153	176	198
West	92	109	120	121	139
US dependent areas	3	3	3	3	3
Subtotal	403	450	492	523	577
Additional gender identity^j
Age at end of year
13–14	0	0	0	0	0
15–19	3	5	6	4	4
20–24	26	30	39	36	49
25–29	46	47	46	53	65
30–34	34	42	58	69	73
35–39	34	38	41	38	39
40–44	21	20	18	24	33
45–49	27	26	26	32	33
50–54	17	18	21	19	22
55–59	16	17	18	14	16
60–64	9	10	8	14	14
≥ 65	6	8	11	12	13
Race/ethnicity
American Indian/Alaska Native	0	1	1	1	1
Asian^b	2	5	5	6	6
Black/African American	102	109	118	128	141
Hispanic/Latino^c	63	68	76	81	97
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	45	49	58	64	79
Multiracial	27	29	34	35	37
Exposure category^d
Sexual contact^e	203	226	255	275	314
Injection drug usef	1	1	1	1	1
Sexual contact^e and injection drug use^f	28	27	28	29	34
Perinatal^g	3	3	3	3	3
Other^h	4	4	5	7	9
Region of residenceⁱ
Northeast	110	129	138	143	155
Midwest	37	40	52	59	67
South	72	72	79	81	90
West	20	19	23	32	49
US dependent areas	0	1	0	0	0
Subtotal	239	261	292	315	361
Total	11,454	12,094	12,760	13,328	14,087

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^c Hispanic/Latino persons can be of any race.
^d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
ⁱ Data are based on address of residence at the end of the specified year (i.e., most recent known address).
^j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 19a. Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year, assigned sex at birth, and selected characteristics, year-end 2021—United States
	13–14 years		15–17 years		18–19 years		20–22 years		23–24 years		Total
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Sex at birth
Male	300	6.6	726	10.9	1,689	38.6	8,732	131.9	11,129	255.6	22,576	85.1
Female	299	6.9	630	9.9	644	15.4	1,842	29.0	2,065	49.2	5,480	21.6
Race/Ethnicity
American Indian/Alaska Native	1	1.3	3	2.7	16	22.5	42	38.5	46	64.3	108	24.8
Asian^b	39	8.7	56	8.3	52	11.3	166	23.3	210	41.5	523	18.7
Black/African American	338	27.5	833	47.4	1,338	114.8	6,064	333.5	7,160	594.7	15,733	219.2
Hispanic/Latino^c	81	3.5	229	7.0	537	25.9	2,549	84.1	3,360	174.1	6,756	53.6
Native Hawaiian/Other Pacific Islander	0	0.0	3	11.4	5	29.4	14	54.8	13	75.7	35	33.7
White	88	2.0	148	2.2	269	6.0	1,307	19.1	1,811	39.8	3,623	13.5
Multiracial	52	13.7	84	16.4	116	37.6	431	98.1	590	217.7	1,273	66.6
Transmission Category^d
Male sex at birth^e
Male-to-male sexual contact^f	5	—	248	—	1,290	—	7,698	—	9,848	—	19,089	—
Injection drug use^g	0	—	2	—	5	—	71	—	126	—	204	—
Male-to-male sexual contact^f and injection drug use^g	1	—	4	—	21	—	174	—	341	—	541	—
Heterosexual contact^h	1	—	11	—	28	—	219	—	308	—	566	—
Perinatalⁱ	236	—	364	—	278	—	500	—	457	—	1,834	—
Other^j	57	—	97	—	67	—	72	—	50	—	343	—
Subtotal	300	6.6	726	10.9	1,689	38.6	8,732	131.9	11,129	255.6	22,576	85.1
Female sex at birth^e
Injection drug use^g	1	—	6	—	27	—	108	—	156	—	296	—
Heterosexual contact^h	6	—	75	—	221	—	1,027	—	1,320	—	2,648	—
Perinatalⁱ	224	—	456	—	304	—	633	—	552	—	2,169	—
Other^j	69	—	93	—	92	—	74	—	38	—	366	—
Subtotal	299	6.9	630	9.9	644	15.4	1,842	29.0	2,065	49.2	5,480	21.6
Region of residence^k
Northeast	94	6.7	242	11.5	345	23.1	1,557	71.1	1,980	141.1	4,218	49.2
Midwest	140	7.5	236	8.6	356	19.8	1,569	56.5	1,936	108.9	4,237	38.6
South	261	7.5	638	12.6	1,249	38.1	5,874	118.1	7,115	216.8	15,137	75.5
West	104	4.9	240	7.7	383	19.2	1,574	51.9	2,163	103.5	4,464	36.1
Total^l	599	6.7	1,356	10.4	2,333	27.2	10,574	81.5	13,194	154.3	28,056	54.0

Note: Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^c Hispanic/Latino persons can be of any race.
^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Data include transgender and additional gender identity persons.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Diagnoses of HIV Infection in the United States and Dependent Areas, 2021: Tables

Report Contents

Other Reports